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Abstract
Osteopontin (OPN) is a phosphorylated acidic glycoprotein that has been shown to play a
vital role in tumourigenesis and metastases. The objective of this study was to determine the
expression of OPN and its receptors (CD44 and integrin αvβ3) in several salivary gland
cancers, and assess its clinical correlations.
Immunohistochemical techniques were used to semi-quantify the level of OPN expression
and its receptors in normal salivary glands and different types of salivary gland tumour.
Our results show that in tumours of salivary gland origin, higher levels of OPN were detected
in tumours which were malignant compared to those which were benign. OPN expression
levels were moderately correlated with pathological grade in MEC and ACC, and with CD44
in PLGA. Integrin αvβ3 was consistently expressed in ACA. Thus, OPN has a potential role
as a prognostic marker for salivary gland tumours.

Keywords
Osteopontin (OPN), HCAM/CD44, integrin αvβ3, salivary gland tumour, pleomorphic
adenoma (PA), acinic cell carcinoma (ACA) , adenoid cystic carcinoma (ACC),
mucoepidermoid carcinoma (MEC), polymorphous low grade adenocarcinoma (PLGA)
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Chapter 1

1

Introduction

1.1 Salivary Glands (SGs)
Human saliva is produced by 3 pairs of major SGs and numerous minor mucous and
serous SGs. The 3 major SGs are: 1) parotid glands (PGs), 2) submandibular glands
(SMGs) and 3) sublingual glands (SLGs). There are approximately 600 to 1000 minor
SGs dispersed throughout the upper aerodigestive tract (1, 2, and 3).
Parotid Gland (PG)
PGs are the largest paired SGs by size but are only responsible for producing
approximately 25% of the total volume of saliva (1, and 3). Its autonomic function is
influenced by parasympathetic fibres from the inferior salivary nucleus via the lesser
petrosal nerve, a branch of the glossopharyngeal nerve (4). PGs are contained within a
dense fibrous capsule along with lymphatic tissues located in close proximity to the
ramus of the mandible. In an adult, it weighs about 15-30g. It contains 2 lobes, a
superficial lobe and a deep lobe (4). The 2 lobes are separated anatomically by the facial
nerve and its branches. PGs secrete saliva via Stenson’s ducts, which pierce through the
buccal mucosa at the level of the maxillary second permanent molar. The superficial
lobe represents 75 – 80% of a PG, while the deep lobe represents 20 – 25%. Up to 80%
of all SG neoplasms occur in the PGs, and the majority of them occur in the superficial
lobe (1, 2, and 3). PGs consist mainly of serous cells with multiple fibrous septa dividing
the individual lobules.
Submandibular Gland (SMG)
SMGs are the second largest paired SGs, and are responsible for secreting up to 70% of
the total salivary volume (3). Its autonomic function is influenced by parasympathetic
fibres from the superior salivary nucleus via the chorda tympani, a branch of the facial
nerve. It weighs approximately 7 to 10 g and is located within the submandibular triangle
on the medial surface of the mandible below the mylohyoid muscle. In an elderly
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individual, the inferior aspect of the SMG is often visible below the angle of the
mandible. Saliva produced from SMGs is secreted into the oral cavity via Wharton’s duct
which opens just lateral to the frenulum of the tongue in the anterior floor of the mouth.
SMGs account for up to 80% of sialolithiasis due to the torturous and up-sloping course
of Wharton’s duct (1). SMGs contain mostly mucous glands that are capped with
crescent-shaped serous demilunes.
Sublingual Gland (SLG)
SLGs are the smallest of the major SGs. They are located within the oral cavity just
above the mylohyoid muscle and immediately below the mucosa of the floor of the
mouth (2, and 3). They have the same innervation as the SMGs, and each weighs only 3
g (2, and 3). SLGs often secrete saliva via multiple small ducts, called the ducts of
Rivinus, which can drain either directly into the floor of the mouth or into Wharton’s duct
or through the sublingual duct of Bartholin. Neoplasms are rarely found in SLGs, but,
the neoplasms of the SLG are often malignant. Their lymphatic drainage is into both the
submental and submandibular lymph nodes (4). SLGs contain mixed cell types,
composed of both mucous cells and serous demilunes.
Minor Salivary Glands
There are more than 600 minor SGs scattered throughout the oral cavity and upper
aerodigestive tract (1, 2, and 3). They are composed of aggregates of mucous glands and
ducts which are not encapsulated. They secrete saliva directly into the oral cavity via
individual ducts. There is a set of unique minor salivary glands, called Von Ebner glands
(VEG), located within the crypts of circumvallate papilla in the dorsum of the tongue.
The saliva from VEG contains lipase as well as normal salivary proteins (4).

1.2 Structure of Salivary Glands
SGs empty into the oral cavity via a main excretory duct, which progressively divides
into smaller interlobar and intralobular ducts that drain the lobes of SGs (4). The striated
duct, which is part of intralobular duct, plays a significant role in the modification of
saliva produced by secretory units, while the intercalated duct connects secretory units to
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the striated duct. Salivary gland units contain secretory and non-secretory acinar cells
and ductal cells (4).
Cell Types
There are 3 main cell types found within the secretory units: mucous cells, myoepithelial
cells and serous cells (4). Mucous and serous cells are the main secretory cells of the
SGs, which differ in their structure and secreted end products (4).
Serous cells are pyramidal in shape with spherical nuclei. They produce proteins and
glycoproteins that contain antimicrobial, enzymatic and calcium-binding functions. Their
secretory granules are deeply basophilic with hematoxylin and eosin (H&E) stains (4).
Mucous cells are tubular in shape and are arranged adjacent to each other around a large
central lumen. The end product of mucous cells is mainly mucins which function
primarily as lubricants. The mucous appears unstained with routine H&E, however,
mucous can be stained using special stains such as Periodic Acid-Schiff (PAS) or Alcian
blue (1, and 4).
Myoepithelial cells are epithelial in origin but contain contractile elements similar to
smooth muscle cells. They surround the intercalated ducts and secretory units of SGs.
These cells appear flattened and lie between the basal cytoplasmic membrane of secretory
or ductal cells and the basement membrane. Contractions of myoepithelial cells aid the
secretion of saliva by acinar cells into the lumen, and the propulsion of saliva from the
intercalated duct towards the striated duct and eventually to the excretory duct (4).

1.3 Saliva
The production and secretion of saliva occurs in 2 stages under the control of the
autonomic nervous system, gustatory system and olfactory system. The first stage occurs
in the acinar cells, under the influence of neurotransmitters, and results in the activation
of ion channels causing fluid secretion, which is an isotonic secretion. As this fluid
travels down the ductal system, the second stage of salivation occurs. This involves fluid
and electrolyte reabsorption rendering the saliva hypotonic. The final saliva contains
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trace amounts of serum protein. However, in disease states, especially inflammatory
conditions, the level of secreted proteins can greatly increase (5).
The main functions of saliva are: 1) to lubricate the oral mucosa to prevent drying and
trauma, 2) to aid in the digestion of food, 3) to mediate taste, 4) to control microbial
overgrowth, and 5) to maintain oral pH to aid remineralization of teeth (5).
(1)

Saliva acts as a barrier against irritants, carcinogens and desiccation from mouth

breathing. It also protects the oral mucosa from physical trauma during mastication and
speech production (5).
(2)

Saliva contains the hydrolytic enzymes amylase and lipase. Their role in

digestion is somewhat redundant in a healthy adult because (1) the transit time in the oral
cavity and the esophagus is insufficient for the enzyme to work effectively, and these
enzymes are degraded by acid in the stomach, (2) bile salts produced from the liver and
excreted from the gall bladder emulsify lipids and allow lipase to work more effectively
in the small intestine, and (3) the pancreas secretes amylase and numerous
disaccharidases to breakdown polysaccharides into absorbable forms. However, in young
infants, especially those born pre-term, the production of pancreatic enzymes is very low,
and infants are dependent on oral amylase to digest breast milk or infant formula (6).
(3)

Saliva acts as a solvent for chemicals in food. It also acts as a vehicle by which

these chemicals are delivered to the taste buds. It should be noted that patients with
xerostomia complain of a decreased sensation of taste (7).
(4)

Proteins related to the innate and humoral immune systems are secreted in saliva.

These proteins include lysozymes, salivary peroxidases, lactoferrin, histatins and
secretory IgA (sIgA) (5). These secretory proteins have antimicrobial properties and
assist in viral neutralization. Histatins are low molecular weight proteins rich in histidine
and have potent antifungal activity. It has been shown that people whose saliva is low in
histatins are more susceptible to oral thrush (8).
(5)

Acidic environments can cause the demineralization of teeth. Saliva is

supersaturated with calcium and phosphate to help stabilize the ion flux on the tooth
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surface. As well, the bicarbonate in the saliva helps buffer the pH of the oral cavity to
maintain a neutral pH which favours remineralization of dentition (5).
Over the past decade, saliva has been a useful adjunct in the diagnosis of clinical
diseases, for example, measuring the cortisol levels in saliva for Cushing syndrome (9).
Recently, other cellular proteins have been identified in whole saliva such as IL-1β, IL-6,
IL-8, and OPN (10, and 11).

1.4 Pathology of the Salivary Glands
There are many different abnormalities and diseases of the salivary glands, including
developmental conditions, infections, immune-related disorders, neoplasms and
inflammatory conditions. Inflammatory conditions are the most common, especially the
mucocele, cases of which are readily available to use as salivary gland control tissue in
the study of salivary gland neoplasia.

1.4.1.1

Mucocele

Mucoceles are often found in the minor salivary glands, especially on the lower lip in a
paramedian fashion. Mucoceles are often painless. However, larger lesions can cause
mild discomfort. They are best described as soft, fluid-filled vesicles that are fluctuant
and often measure less than 1 cm in diameter. They appear bluish in colour because of
the mucin. However, deeper mucoceles are frequently grayish in colour, and found on
the ventral surface of the tongue and the floor of the mouth (1, 2, and 3).
Clinical Behaviour
Mucoceles are benign and occur commonly on the lower lip in all age groups. They are
associated with a history of trauma. However, many patients do not recall a traumatic
insult. Other lesions that may appear blue must also be considered in the differential
diagnosis; especially low grade mucoepidermoid carcinomas. Cavernous hemangiomas,
lymphangiomas and venous varices may also give a similar appearance. Although rare, a
vascular leiomyoma appears blue and has a predilection for the lower lip as well (1, 2,
and 3).
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Histological Features
Microscopically, mucoceles appear as granulation tissue surrounding mucin without a
true epithelial lining. This is a distinguishing feature from mucous retention cysts. In
addition, neutrophils and foamy histiocytes are usually present in mucoceles (1, and 3).
Treatment and Prognosis
Minor salivary gland mucoceles are managed by local excision of the associated salivary
gland as well as the overlying epithelium. Excision can help establish the diagnosis and
cure the condition with little chance of recurrence. However, care must be taken during
the excision as to not transect another minor salivary gland, as this can produce a new
mucocele in the same location (2).

1.4.2

Salivary Gland Neoplasia

SG carcinomas represent approximately 3% of all head and neck malignancies excluding
lymphoma. In general SG tumours comprise less than 0.5% of all malignancies. In
Canada, the annual incidence of SG tumours is between 2 – 3 cases per 100,000
population. The trend of SG tumours in Canada over the past 15 years had been
relatively stable. Unlike the most common head and neck neoplasm, squamous cell
carcinoma (SCC), smoking and heavy alcohol consumption do not appear to be risk
factors for SG tumour development. However, there are suggestions from the literature
that occupational exposures to volatile solvents and early exposure to ionizing radiation
may lead to the development of certain SG tumours (1, and 3).

1.4.2.1

Benign Salivary Gland Tumours

There are a number of different benign salivary gland tumours including basal cell
adenoma, canalicular adenoma, ductal papillomas, Warthin’s tumour, oncocytoma and
myoepithelioma. By far the most common is the pleomorphic adenoma (PA).

1.4.2.1.1

Pleomorphic Adenoma (PA)

Pleomorphic adenomas (PAs) are the most common form of salivary gland tumours. Up
to 75% of all PAs occur in the parotid gland, and the majority of PAs are located in the
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superficial lobe. However, they can arise from submandibular, sublingual and minor
salivary glands as well. The peak incidence of PAs occurs between the 4th and 7th
decade of life, and there is a slight female predilection with a 1.4 to 1 female to male ratio
(1, 2, and 12).
Clinical Behaviour
Patients with PAs often present with a slow-growing, mobile, painless mass of unknown
duration. The usual presentation is commonly noted as an incidental finding by a
physician or a dentist during a clinical examination for an unrelated issue. Most PAs are
found in the superficial lobe of parotid gland, and they rarely cause facial paralysis due to
compression. However, when a PA is found in the deep lobe of the parotid gland, it can
extend into the parapharyngeal space causing obstructive symptoms. When present in
minor salivary glands, PAs present as a submucosal mobile mass usually without
ulceration, but when noted in the palate, it is often fixed because palatal mucosa is tightly
bounded to underlying bone. Although, benign and slow growing in nature, if left
untreated, up to 3 – 4% of PAs may become carcinoma ex-pleomorphic adenomas, which
are aggressive malignancies that may metastasize and result in death (13).
In general, the etiology of PAs is unknown. However, in a subset of PAs, there appears
to be a decreased expression of p53, a tumour suppressor gene, and Ki-67, a cellular
marker for proliferation (13, and 14). As well, the MUC1 gene appears to play a role in
the recurrence of PAs after surgical intervention (15).
PAs are composed of neoplastic myoepithelial cells mixed with neoplastic ducts and
stroma. Certain cellular markers had been implicated in the malignant transformation of
PAs. The down-regulation of neural cell adhesion molecule (N-CAM) and a cytoplasmic
accumulation of β-catenin in PA are suggestive of malignant transformation (16).
A thorough history and physical examination is vital to aid in the diagnosis and treatment
of PA. However, imaging such as CT scans and MRIs can determine the location and
extent of the lesion. Fine needle aspiration is useful, however, if it is negative or
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indeterminate, an incisional biopsy of a representative tissue sample can help yield a
definitive diagnosis (2).
Histological Features
PAs are characterized by heterogeneity of cytology and architecture. Heterogeneous in
nature, PAs can be broadly sub-classified into cellular and myxoid types (1, and 12).
The cellular type of PAs is mainly derived from scattered mucoid material separating the
epithelial elements into small groups of ductal structures, cellular nests, anastomosing
cords or foci of keratinizing squamous cells. In comparison, the myxoid type of PA is
composed of mesenchymal-like elements such as myxoid, chondroid, hyaline and
osseous regions with fewer epithelial components (12). Cellular PA is often surrounded
by a complete fibrous capsule of varying thickness with occasional small extensions of
neoplastic cells (12). However, myxoid types often have incomplete capsules, yet they
are often well demarcated from normal salivary gland tissues which allows for complete
surgical excision. Recurrence of PA is rare, and it is mainly due to incomplete excision
of the primary tumour or seeding of tumour in the surrounding tissue due to the rupture of
the tumour during excision. When it recurs, it is often multi-focal (1, and 2).
Treatment
The treatment of choice for PA is excision with a negative margin. As the majority of
PAs arise from the superficial parotid gland, the preferred treatment is a superficial or
total parotidectomy with facial nerve preservation (2). However, if the tumour is located
close to the main trunk of the facial nerve, capsular dissection has been shown to have a
greater than 95% success rate in achieving local control of the tumour. Because of the
high success rate of local control with surgical intervention alone, post-operative
radiation therapy (RT) is no longer advised, however, RT maybe used when PAs are
located in minor salivary glands that are not amenable for surgical resection (1, and 2).
Prognosis
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The clinical outcome for surgical resection with negative margins for primary PAs has
been reported to have a 99% success rate without recurrence for greater than 10 years
(17). However, the success rate is only 70% at 10 years if repeated surgical intervention
is required (18). The risk of major complications is low; however, the risk of
complications is increased with salvage surgery for recurrent PA. The likelihood of
malignant transformation increases with the age of the patient and the duration of the
neoplasm (1, and 2).

1.4.2.2

Malignant Salivary Gland Tumours

As with benign salivary gland tumours, there is a variety of different malignant salivary
gland neoplasms, some of which are rare. To ensure sufficient available tissue for
research, this thesis investigates the 4 most common types.

1.4.2.2.1

Acinic Cell Adenocarcinoma (ACA)

Acinic cell adenocarcinomas (ACAs) are rare salivary gland tumours which account for
approximately 3% of all salivary gland malignancies. ACAs are almost exclusively
found in the parotid gland, in up to 80 - 99% of cases (1, 2, 3, and 12), but only accounts
for 2 – 4% of all parotid gland tumours.
Clinical Behaviour
ACA can appear in all age groups with a median age of occurrence at 52 years, which is
slightly earlier than most other salivary gland malignancies. Like other malignant
salivary gland neoplasms, ACA affects slightly more females than males with a ratio of
3:2. ACA often presents as a painful mass within the parotid gland. As it enlarges it can
affect peripheral nerves and nodal metastases can occur in 1 out of 5 cases. Another
unique aspect of ACAs is that 3% are found bilaterally, which ranks second only to
Warthin’s tumour (up to 15%) in bilateral occurrence (1, 2, and 3).
Histological Features
ACAs are often well circumscribed and may show some encapsulation, especially in the
minor salivary glands. Acinar cells are rounded or polygonal in shape, have uniform,
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eccentric nuclei and PAS positive cytoplasmic granules. Ductal cells tend to form a
syncytium and lack features of the other cells. Atypia may be present, but mitotic
figures are infrequent and are usually found in ductal cells. The stroma is usually
fibrovascular but may be hyalinized. A unique feature is the frequent presence of a
lymphoid infiltrate which contains germinal centres. Although encapsulated, evidence of
infiltration is often seen, yet, this does not correlate with clinical behaviour.
Multinodularity, hyalinization and infiltration are often seen in recurrent and
metastasizing tumours (1, and 12).
Treatment and Prognosis
ACAs tend to have a favourable outlook with a 10-year survival rate of 70-85%. Some
long term data suggests 20-year survival rates of over 65%. However, the poorest
prognosis of ACA has been associated with high grade lesions or the presence of
metastatic disease at the time of diagnosis (1, and 3).
It is widely believed that surgical excision is the primary mode of therapy for ACA.
Although, there is debate over which form is preferable: local excision versus radical
excision. Recent literature has suggested a less aggressive surgical approach for a
localized lesion with negative node status (2). Post-operative radiation therapy is often
employed to improve the clinical outcome. However, emerging data suggests that
neutron beam radiation is more effective than conventional radiation. Unfortunately, like
many salivary gland malignancies, ACA is highly resistant to chemotherapy (2).

1.4.2.2.2

Adenoid Cystic Carcinoma (ACC)

Adenoid cystic carcinomas (ACCs) are the second most common type of malignant
salivary gland neoplasms and account for 25% of all malignant salivary gland tumours.
It is most commonly found in the submandibular gland. In parotid glands, it constitutes
up to 15% of all malignancies. It is rarely found in the sublingual gland. In minor
salivary glands, more than half of ACCs occur in the palate. It has a wide age
distribution; however, it is often diagnosed between the 4th and 6th decades of life, with
a slight female predilection (female to male ratio of 3:2) (1, 3, and 12). Like many other
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salivary gland malignancies, ACC has no known etiology. However, there is evidence
that some forms of aggressive ACC are involved with p53 tumour suppressor gene
inactivation (19, and 20).
Clinical Behaviour
ACCs often grow very slowly and have a relatively indolent but relentless course. Often
it can present as a firm painless mass that progressively enlarges. Advanced tumours
may present with pain and nerve paralysis. ACC have a propensity to invade peripheral
nerves. Although, ACC have a good 5 year survival rate of approximately 90%, because
of the associated perineural invasion at the time of definitive treatment, it often recurs
and recurrences have a poor 15 year survival rate of less than 40% (1, 2, and 3).
Unlike most carcinomas, ACC seldom metastasizes to regional lymph nodes. However,
distant metastases are common in late diagnoses. The lung is the most common site of
metastases, while the liver is the second most common location. Bone metastases
indicate a fulminant course of ACC and are associated with a guarded prognosis (1, 3).
Histological Features
The diagnosis of ACC is made by histological assessment of a biopsy or surgical
resection specimen. There are three major histological patterns of ACC: (1) cribriform,
(2) tubular and (3) solid. The solid pattern is often associated with a clinically aggressive
course. The tumours are classified based on the predominant histological type, as ‘pure’
patterns rarely occur. Rather, there tends to be a combination of two or three patterns
within a single tumour (1, and 12).
The classic cribriform type is composed of small, basophilic, uniform cells that are
arranged into islands or anastomosing cords, with a pathognomonic “Swiss-cheese”
pattern. The tubular type is composed of either single or multiple layers of basaloid cells
that are arranged in small ducts with a single lumen. The solid type, unlike the cribriform
or tubular types, is composed of sheets of basaloid cells with scanty cytoplasm and often
with central areas of necrosis (1, and 12).

12

Treatment
Primary treatment of ACC is complete surgical resection of the tumour if possible.
However, some studies had advocated post-operative radiotherapy, which can limit local
failure from microscopically positive margins. Unfortunately, ACCs are resistant to
chemotherapy, thus radiation therapy is used for metastatic disease (2).
Prognosis
The solid type of ACC shows the worst clinical outcome of all 3 histological patterns (1).
The long term survival of ACC remains low. This is due to its high rate of perineural
invasion and its infiltrative characteristics which pose a challenge for the surgeon to be
able to achieve a clean surgical margin (2).

1.4.2.2.3

Mucoepidermoid Carcinoma (MEC)

Mucoepidermoid carcinomas (MECs) are the most common form of all malignant
salivary gland tumours. However, it only accounts for 10 - 15% of all salivary gland
tumours. It is most commonly found in the parotid gland. The peak incidence of MEC
occurs between the 3rd and 5th decades of life, with a slight female predilection. It is
also the most common salivary gland malignancy in children (1, 3, 4, and 12).
Clinical Behaviour
Patients with MEC often complain of a painless, solitary, firm mass. The majority of
patients are asymptomatic during the early course of the disease, though, over time,
patients with high grade or advanced lesions will report symptoms such as tenderness,
pain, drainage, and dysphagia. When lesions are located in the parotid gland, trismus and
facial nerve paralysis can occur (2). In rare instances, MECs show an accelerated growth
pattern without a period of slow or absent growth (2).
In minor salivary glands, MEC are often discovered incidentally during a dental
examination. They are often found in the palate, retromolar pad, floor of the mouth,
buccal mucosa, lips or tongue. These MECs present as a bluish smooth submucosal
swelling that can often be mistaken for a mucocele. Sometimes, a small discharge
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through the mucosal surface may be interpreted as a draining dental abscess. Over time,
these swellings become symptomatic with paresthesia or numbness of the dentition,
ulceration or hemorrhage (1, 2, and 3).
Histological Features
The etiology of MEC is unknown. Diagnosis of MEC is based on clinical and
microscopic examination of the lesion. Histologically, it is usually divided into 3 main
types of cells: (1) mucin producing mucous cells, (2) intermediate cells, and (3)
epidermoid cells with squamous differentiation. The term ‘mucoepidermoid’ is derived
from the combination of mucous and epidermoid cells found within the lesion. Aside
from the 3 main cell types, columnar and clear cells are occasionally found, which can
proliferate in a focal area or combine with the main cell types in a cystic or solid pattern
(1, and 12).
Mucous cells are the neoplastic cells containing mucin that are important for the
diagnosis and subsequently for determining the prognosis of the MEC. Mucous cells are
relatively large with polymorphism and have foamy cytoplasm resembling the mucous
acini of normal salivary glands. In most MECs, mucous cells often constitute less than
10% of the lesion. They are more prevalent in low grade rather than in high grade
lesions (1, and 12).
Intermediate cells are highly proliferative, and are found in small clusters or in solid
sheets combined with mucous and epidermoid cells. There is a gradual transition of
intermediate cells from the smaller basaloid cells to larger cells that are 2 to 3 times the
size of the original basaloid cells.

Further increases in size and content lead to the

identification of epidermoid cells. Thus, at the late stage of differentiation of
intermediate cells, it is often difficult to distinguish large intermediate cells from
epidermoid cells (1, and 12).
Epidermoid cells tend to form small nests or they line the cystic spaces that contain
mucous and intermediate cells. Occasionally, they form keratin pearls or they are
individually keratinized, which can indicate an inflamed tumour (1).
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Grading
MEC is divided into low, intermediate and high grades. In low grade lesions, prominent
cystic structures of varying sizes are filled with mucin. Cysts are mainly lined by a
single layer of mucus-secreting columnar cells with few mitotic figures and little cellular
atypia (12). With intermediate lesions, there are solid areas of squamous cells and
intermediate basaloid cells with increasing cellular atypia, mitotic figures and an
increased nuclear to cytoplasmic ratio (1, and 12). In high grade lesions, nests of
intermediate basaloid cells and epidermoid cells are present with few cystic components.
Ductal structures are rarely found. There are high numbers of mitotic figures, greater
than 4/10 high power fields (hpf), sometimes with necrosis and perineural invasion (9).
Tumour makers (p27 and Ki-67) have been identified which correlate with aggressive
behavior and a poor prognosis. (21)
Treatment and Prognosis
The main treatment of MEC is surgical intervention. The overall 5-year survival rate of
MEC is over 85%. More specifically, the 5-year survival rate of low grade lesions is
greater than 90%, while for high grade lesions, it is below 50% (1, and 2). Yet, overall
outcome mainly depends on the clinical stage, tumour grade and location of the MEC.
Although, tumour grade may predict the aggressiveness of the lesion, it is now known
that the TNM clinical staging system is a better indicator of prognosis in patients with
MEC. MEC often metastasizes to bone, the lungs and the brain, which implies poor
prognosis (1, and 2). Patients usually succumb to the disease due to local recurrences or
distant metastases.

1.4.2.2.4

Polymorphous Low Grade Adenocarcinoma (PLGA)

Polymorphous low grade adenocarcinoma (PLGA) is almost exclusively found on minor
salivary glands, with the palate being the most common site. Its peak incidence is
between the 3rd to 7th decades of life, with a median at the mid-6th decade. PLGA has a
slight female predilection (1, and 12).
Clinical Behaviour
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PLGA is a slowly growing, often painless mass. It is considered to be a low grade
neoplasm with a good long term prognosis and almost no metastatic potential. Early
lesions can often be mistaken for a benign lesion such as a pleomorphic adenoma
microscopically if the surgical biopsy specimen is small and inadequate. Because it
presents as a palatal mass with an intact mucosal surface, it can be clinically mistaken for
pleomorphic adenoma as well. Adenoid cystic carcinomas and low-grade
mucoepidermoid carcinomas should be considered in the clinical differential diagnosis
(1, 3, and 12).
Histological Features
Microscopically, it appears as a non-encapsulated lesion with infiltrative borders and a
variable growth pattern. Several patterns occur: tubular, solid, papillary, microcystic,
cribriform, fascicular, pseudo-adenoid cystic, or strand-like. Occasionally, the nuclei are
hyperchromatic but are usually open faced. Mitotic figures are rare. The stroma may be
fibrous, myxoid, or hyalinized. PLGA may demonstrate significant infiltration with
invasion of small nerves, vessel walls, and bone, which belies its low-grade behaviour.
Central necrosis is not seen. The peculiar histologic pattern of the tumour does not
appear to relate to its clinical behaviour. Special cellular markers such as alpha-smooth
muscle actin, and c-kit have been used to distinguish equivocal cases of ACC and PLGA
(22).
Treatment and Prognosis
Primary treatment for PLGA is surgical excision with 1.5 cm peripheral margins. This is
despite the tumour’s tendency for perineural invasion and its lack of a capsule (2). The
decision to pursue a palatectomy depends on radiographic or clinical evidence
demonstrating erosion of the palate. Radiotherapy is not as effective as surgery and is
often not required (2).
PLGA generally has a good prognosis with a 5 year survival rate of 85%. Recurrence
and distant metastases are rare if the surgical margins are negative. Like many
carcinomas, PLGAs first metastasize to regional lymph nodes and then metastasize to
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lungs and bones. Primary treatment remains surgical excision with wide peripheral
margins and often involves partial maxillectomies or mandibulectomies (2). Radiation
therapy may be used post-operatively to improve clinical outcomes (2).

1.5 Osteopontin (OPN) and its receptors
1.5.1

Osteopontin (OPN)

Osteopontin (OPN) is an acidic phosphoglycoprotein and is a member of the SIBLING
(Small integrin-binding ligand N-linked glycoprotein) family, which also includes bone
sialoprotein, dentin matrix protein-1, dentin sialophosphoprotein, and matrix extracellular
phosphoglycoprotein, which can modulate cell behaviour by autocrine and paracrine
mechanisms by interacting with cell surface receptors such as integrin (23). This glycinearginine-glycine-aspartate-serine (GRGDS) integrin binding motif is also presented in
fibronectin, vitronectin and a variety of extracellular proteins that bind to members of the
integrin family of cell surface receptors.
OPN is a monomer protein which undergoes extensive post-translational modification
including phosphorylation, glycosylation, and cleavage at variable sites. This results in a
variable molecular mass that ranges from 25 to 75 kDa. Originally, OPN expression was
generally considered to be limited to the bones and dentition of adults, because OPN is
highly expressed in bone matrix, and is regulated by osteotropic hormones (24).
However, studies since the mid-1990s have found OPN expression in numerous soft
tissues such as kidneys, mammary glands, and salivary glands (25, 26, 27, 28, 29, and
30).

1.5.2

OPN gene, its structure and adhesion motifs

In 1992, Crivello isolated the cDNA and gene encoding for OPN and concluded that
OPN is poorly to moderately conserved between several species of animals including
humans. Yet, its functional domains are conserved. Its amino and carboxylic terminal
regions and the approximately 50 amino acids surrounding the RGD signaling sequence
demonstrated the highest levels of conservation. (31) These include acidic residues,
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RGD integrin binding domains, similar phosphorylation and glycosylation motifs and
sites for controlled proteolysis (23).
In humans, the OPN gene is mapped to chromosome 4q13, and Bg/II restriction fragment
length polymorphism (RFLP) has been described. A particular RLFPs mouse OPN allele
has been described to enhance resistance to infection by bacteria. The mechanism of
resistance may involve the interference of Ca2+ uptake or the interaction of the causative
agent with the host cell surface receptor (32).
Numerous growth factors, hormones, tumour promoters and oncogenes are involved in
the regulation of OPN expression. Denhardt sequenced 1kb upstream of the mouse OPN
promoter region and searched for transcription factor recognition sites. Aside from the
characteristic promoter regions such as TATA box, CCAAT box, and GC box, other
recognition sites such as Sp1, CTF/NF-1 and AP-1, were found. These regions and sites
may have contributed to the ubiquitous nature of OPN gene expression in various tissues
(26). OPN expression is also augmented at higher levels in different transformed cell
lines compared to the non-tumourigenic counterparts (33).
The RGD integrin binding domain mediates interactions via αvβ1, αvβ3, αvβ5, αvβ6, α5β1,
and α8β1 (34, 35, 36, and 37). Adjacent to the RGD domain at the C-terminus is a cryptic
SVVYGLR sequence that is exposed upon cleavage with thrombin. This cryptic domain
interacts with more integrins such as α4β1, α4β7, and α9β1 (38, 39, and 40). Aside from
binding with integrin, OPN also interacts with CD44, a hyaluronic acid receptor (41). A
number of different CD44 isoforms exist, as the mRNA of CD44 has a variable splicing
region where 10 variant exons exist via differential splicing. OPN does not bind to the
standard isoform (42), but, OPN binds to some of the CD44 splice variants such as v6
and v7 (43). However, the exact mechanism of domain binding has not yet been
elucidated (44).

1.5.3

OPN physiologic functions

Immune response
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An increase in OPN transcription has the ability to activate T-lymphocytes, thus the
alternative name for OPN is ‘the early T-lymphocyte activation gene 1’ (Eta-1) (32, and
33). Early research has shown that Eta-1/OPN has the ability to enhance resistance to
flaviviruses and Rickettsia infection. In mouse models, rotavirus infections induce OPN
expression, which decreases the severity of the disease. OPN deficient mice infected
with rotavirus demonstrated more severe diarrhea when compared to wild type mice.
OPN acts as a potent chemoattractant that aids the maturation of macrophages, which
upregulate their own OPN expression via autocrine routes. It has been demonstrated that
upregulation of OPN occurs with ischemic injury such as stroke, acute tubular necrosis
and myocardial necrosis (45, 46, and 47). However, with activation of T-lymphocytes
and the recruitment of activated macrophages, increased OPN expression may actually
increase the amount of tissue damage.
Although, there are low levels of OPN expression in neutrophils, OPN is important for
the recruitment and migration of neutrophils. In two separate experiments using OPNnull mice, a reduced chemotaxis of neutrophils was demonstrated in sodium periodate
induced peritonitis and concanavalin-A induced hepatitis in liver (48, and 49).
Interaction of OPN with neutrophils has been identified via α9β1 integrin binding (50).
Osseous function
OPN, a secreted acidic glycosylated phosphoprotein, contains a high content of serine
and aspartate residues, which are associated with osteocalcin (51). It has the ability to
bind to the hydroxyapatite matrix of bone via the aspartic acid-rich region. OPN is
secreted by osteoblasts, osteocytes and osteoclasts, and highly expressed in chondrocytes
days before the onset of mineralization (52). It is found in abundance in cell-matrix and
matrix-matrix interfaces in mineralized tissues. It is hypothesized that OPN may protect
the surface of exposed bone or prime it for cell-matrix interaction (53). It acts as an
opsonin to facilitate macrophage binding to mineralized tissue debris. It can bind to type
I collagen, fibronectin, and osteocalcin to improve the physical strength of the matrix
(54). However, Rittling (1998) found that mineralization of bone and dentition occurred
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in OPN knock out mice, yet it appears that OPN is involved in bone remodeling, but it is
not essential for it to occur (55, and 56).
Osteopetrosis, a condition of impaired bone resorption caused by a failure of normal
osteoclastic activity, is associated with higher levels of OPN expression in rats (57).
High levels of calcitriol (Vitamin D3) are also associated with osteopetrosis. This is
likely because OPN expression is stimulated by calcitriol, which normally promotes
osteoclast differentiation and bone resorption (57). It is now known that phosphorylation
of the serine residues of OPN is required for proper cell-matrix interaction with β3
integrin and the GDS sequence to stimulate osteoclast attachment (58). Osteoblast
attachment is independent of β3, yet it still requires the GDS sequence.
In vivo experiments found that mechanical stresses on osteoblast-like cells lead to
elevated OPN and Type 1 collagen mRNA (59). It is postulated that the stimulation of
mechanosensitive channels lead to the influx of intracellular calcium ions and modify
gene expression.
Wound Healing
OPN is an important excreted molecule that recruits inflammatory cells to the site of
injury. Whether OPN is pro-inflammatory or pro-healing has not yet been established.
An incisional wound on OPN-null mice showed alterations in the architecture of the
extracellular matrix and collagen fiber diameter, and resulted in more residual debris
(60). Research of localized OPN knockdown using antisense oligodeoxynucleotides,
further supported earlier findings of smaller diameter collagen fibrils when compared to
controls (61).
Macrophages at the wound site of the OPN-null mice expressed increased levels of
mannose receptors, which is associated with reduced pro-inflammatory cytokine
secretion and increased pro-healing cytokines (62). As well, decreased migration of
inflammatory cells at the wound site resulted in a reduction of granulation tissue
formation and scarring with accelerated healing (61). OPN directly binds to type I
collagen and interacts with types II to V. It has a central role in proper collagen
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organization, ECM formation and myofibroblast differentiation via TGF-β1 (63, 64, and
65).

1.5.4

OPN and Pathologies

Atherosclerosis and Vascular Diseases
Atherosclerosis is considered to be a result of chronic inflammation of the vasculature.
Given the role of OPN in inflammatory processes such as T-cell activation and the
recruitment of macrophages, a number of studies have investigated the role of OPN in the
progression of atherosclerosis. A hyperlipidemic mouse model, comprised of mice with
ApoE-deficiency showed an accelerated formation of atherosclerotic lesions as compared
to wild type mice. However, OPN and ApoE deficient mice demonstrated a significant
reduction of atherosclerotic lesions when compared to ApoE only deficient mice after 36
weeks of a normal diet (66). A similar study with a triple knockout of ApoE, LDL
receptor and OPN showed that the OPN deficiency decreased the lesion size of
atherosclerotic plaques (67). In humans, OPN is expressed in smooth muscle cells,
endothelial cells and macrophages in atherosclerotic lesions (68, and 69). Animal models
showed that OPN promotes smooth muscle cell migration and proliferation (70). Thus,
OPN enhances the proliferation, migration and accumulation of smooth muscle cells and
endothelial cells in repair and remodeling processes of the vasculature.
Renal stone and glomerulonephritis
In mice, OPN is abundant in the nephron, particularly at the loop of Henle and distal
convoluted tubules (71). In pathology, OPN can be found in the epithelial lining of
Bowman’s capsule. In tubulointerstitial nephritis, focal increases of OPN can be found at
sites where macrophages accumulate (68).
OPN appears to play a dual role in both the formation of and protection against calcium
oxalate stone formation. When OPN is secreted into the tubular fluid, often in a hypophosphorylated form, it acts to suppress the growth of calcium oxalate crystals by
disrupting the crystallization process (72). In contrast when calcium oxalate crystals are
found, there is also a corresponding increase in the intra-cellular OPN expression in
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epithelial cells. OPN upregulation appears in response to hypoxic and reperfusion
injury. Young kidneys can readily increase OPN production in response to hypoxic
injury as compared to old kidneys, and the OPN production decreases intra-cellular Ca2+
and nitric oxide production thus protecting the cells from injury (26).
Tumourigenesis
Tumourigenesis is a multi-step process (Knudson hypothesis) that transforms normal
cells into neoplastic cells (73, and 74). There are numerous mechanisms within the body
to defend against malignant transformations such as the host immune system and cellular
repair system. However, when tumourigenesis steps escape or evade the cellular and/or
immunological check points, a gradual build-up of non-lethal transformations can
eventually lead to a neoplasm. In order for cells to evade and escape cellular and
immunological mechanisms that can lead to the cells’ destruction, these cells have to
have acquired the following cellular changes and abilities: 1.Evading apoptosis, 2.
Sustaining growth signaling, 3. Inducing angiogenesis, 4. Evading growth suppression, 5.
Replication immortality, and 6. Ability to invade and metastasize.
OPN has been implicated in several of the 6 key characteristics of metastatic neoplasms.
Studies using OPN deficient mice models injected with melanoma cells (75) and breast
cancer cells (76) have implicated OPN in sustaining a more rapid tumour growth.
Recently, He et al. found that the presence of 2 other variant splicings of OPN was a
prognostic factor for tumour aggressiveness and metastasis, especially OPN-c (77, and
78).
Evasion of Apoptosis
Transformed cells are distinct from normal cells, in that transformed cells express
different cell surface antigens that can be recognized by the host immune system and be
removed from the environment via signal induced apoptosis. However, some
transformed cells acquire the ability to alter the apoptotic signal cascade to resist
apoptotic cell death. OPN promotes the migration of lung cancer cells through integrin
αvβ3, which activates the FAK, PI3K, Akt (protein kinase B), ERK and NF-kappaB
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pathways (79). OPN may enhance cancer cell survival by activating the Akt pathway,
upregulating GAS6 (80), and its interaction with CD44 and integrins via inside-out
signaling activation of src (81).
Induction of Angiogenesis
In order to maintain limitless growth potential of tumour cells, tumour cells must acquire
and maintain an independent vascular supply to maintain adequate nutrition. It has been
demonstrated that OPN binding to certain integrin receptors induces angiogenesis (34).
Binding of OPN to integrin αvβ3 increased the expression of vascular endothelial growth
factor (VEGF) in endothelial cells. This overexpression allowed recruitment of
neovascularization. Aside from upregulating VEGF, OPN interacts with integrin αvβ3
and activates connective tissue growth factor and cysteine-rich angiogenic inducer 61,
which enhances neovascularization and tumour growth in vivo (80). OPN signaling via
NF-κB also prevents endothelial cell apoptosis (82).
Invasion and Metastasis
For a malignant tumour to establish a secondary growth site within the host, numerous
events must take place: invasion of the basement membrane and extracellular matrix;
evasion of host immunity via either lymphatic or hematological spread, attachment to a
distant site, and invasion of the basement membrane at the distant site.
The first step of metastasis is the invasion of the tumour cell into the extracellular matrix.
To penetrate through the basement membrane, the tumour cells need to secrete
appropriate proteases. One group of proteases that can enable the degradation of the
basement membrane is the matrix metalloproteinases (MMP). OPN had been shown to
increase expression of MMP-1 and MMP-2 (83). MMP-2 levels correlate with tumour
invasiveness and metastasis in murine melanoma cells (84). Breast cancer cell lines,
when treated with OPN, develop increased levels of urokinase-type plasminogen
activator (uPA). This uPA can indirectly activate MMP-1, 2, 3, 9 and 14 (85, 86, and
87). Each of these MMPs can digest different ECM components thereby playing an
important role in tumour invasion and metastasis.
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Once the tumour cells invade through the ECM and into the lymphatic or vascular
channels, these cells need to survive and avoid detection from the host immune system in
the vascular or lymphatic channels in order to establish a secondary growth centre.
Tumour derived OPN has been shown to inhibit NO-mediated tumour cell apoptosis in
colon adenocarcinoma via inhibition of inducible nitric oxide synthase in lymphocytes
and macrophages and blocking their functions (88).
OPN also plays an important role in establishing bone metastasis. It can activate TGF-β
and bFGF via the upregulation of uPA. Nemoto et al. and Chellaiah et al. were able to
demonstrate a lower incidence of bone metastasis in OPN knock-out mice models
injected with breast cancer cell lines (75, and 89). In addition, they were able to elicit
bone metastasis with the introduction of OPN.
Therapeutic Targets
There are currently several strategies and therapeutic approaches to modulate OPN
activity in tumour cells, especially those of breast cancer. OPN binding to CD44v has
been shown to promote migration and invasion of tumour cells; however, this interaction
requires thrombin cleavage of OPN to expose the SVVYGLR binding site. With this in
mind, a novel treatment using thrombin-inhibitor Argratroban has demonstrated
decreased cell growth, adhesion, and migration in breast cancer cells (90). Another
method is to directly inhibit OPN expression. Agelastatin A inhibits OPN and its use
causes reduced growth, adhesion and invasion of breast cancer cell lines (91). Thus,
targeting OPN appears to be a good approach in cancer management.

1.6 CD44
CD44 is a transmembrane glycoprotein with variable N and O-linked glycosylation sites
belonging to the family of cell adhesion molecules (CAMs) (92). They are ubiquitously
expressed in human tissues especially in the epithelium (93). They control cellular
behaviour by interacting with soluble proteins and the extracellular matrix (ECM) to
maintain tissue integrity. CD44 has 11 isoforms (1 standard and 10 variants) which are
all encoded by a single gene located in the short arm of chromosome 11 in humans with a
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total of 20 exons (94, and 95). All isoforms contain a large ectodomain, a transmembrane
domain, and a cytoplasmic domain. Variants are generated by alternate splicing of exons
6 to 15 mRNA inserting into the variable region in the large extracellular ectodomain
(96). The molecular weight for CD44 ranges from 80 to over 200 kDa (97), however, the
smallest standard isoform of CD44 (CD44s) is approximately 85 kDa (98).
CD44 is involved in many cell-cell and cell-matrix interactions which include adhesion,
migration and lymphocytic functions (99). Thus, by variant splicing, CD44 interacts with
many soluble proteins and ECM, however, the main ligand is hyaluronan (HA) (100). As
well, CD44 interacts with TGF-β, osteopontin, laminin and others (41).
The main physiological functions of the CD44 – HA interaction are: T cell proliferation,
IL-2 production, NK cell cytotoxicity and macrophage production of cytokines and
chemokines. Recent studies have shown that CD44 is involved in various mechanisms of
metastasis. The CD44 isoforms that have been implicated with malignancy include:
CD44s, CD44v3, CD44v5, CD44v6 and CD44v10. Although, HA is the principal ligand
of CD44, it is by no means the only one, osteopontin is one of several non-ECM ligands
which binds to CD44. Binding between OPN and CD44 and its variants occurs via the
RGD independent domain. It has been shown that OPN-CD44s and its variant
interactions facilitate adhesion, migration and stimulation of both normal and
transformed cells via activation of mitogen-activated protein kinase (MAPK) and
PI3K/Akt pathways. As well, CD44 variants co-operate with β1 containing integrins to
bind with OPN to stimulate cell motility and chemotaxis (41). Altered levels of
expression of OPN and CD44v6 were found in odontogenic tumours but not in
inflammatory or developmental odontogenic cysts (101).
The presence of CD44s and CD44v in salivary gland tissue has been reported (102, 103,
104, 105, and 106). Fonseca et al. further characterizes the expression pattern of CD44v
within normal salivary gland tissue (107). They found that 3 main variants exist: 1)
CD44v3 is positive in acinar and myoepithelial cells, but negative in mucus-producing
cells, 2) CD44v5 was consistently negative in all salivary gland tissues, and 3) CD44v6
was found in acinar cell membranes which interdigitated with myoepithelial cells. In
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further studies with CD44 in salivary gland pathology, a down regulation of v3 and v6
was shown to be associated with malignancy and an up-regulation was only associated
with PA (108). Recently, Wang et al. demonstrated CD44v3, v6 and v10 were associated
with head and neck squamous cell carcinoma (HNSCC) (101).
Soluble CD44 (sCD44) had been shown to modulate the function of cell surface CD44
and has been demonstrated to be up-regulated in many cancers. Chang et al. showed that
sCD44v6 was detected in oral squamous cell carcinomas, but was not a clinical
prognosticator for disease progression (109).

1.7 Integrin
Integrins are a family of transmembranous cell adhesion receptors, which are
heterodimeric glycoproteins that are composed of α and β subunits (110). The molecular
weight of an integrin is approximately 280 kDa, the larger α subunit ranges from 150 –
180 kDa, and a smaller β subunit is about 90 kDa (111). There are at least 18 α subunits
and 8 β subunits forming at least 24 combinations known to date (112). They bind to
collagens, laminins, or RGD-containing proteins such as OPN. As well, several integrins
can bind to cellular receptors and viruses such as adenovirus and human
immunodeficiency virus (113). Its net effect is cell-type specific and context dependent,
as integrin mediated adhesion via “outside-in” and “inside-out” activation can regulate
apoptosis, mitogenesis, cell differentiation, cell migration, as well as cell to cell adhesion
(111). Integrin is also involved in the progression of many common diseases such as
neoplasms, tumour metastasis, immune dysfunction, infections, osteoporosis and
coagulopathies (114, and 115).
There are several signal transduction pathways via integrin interactions, one of which is
focal adhesion kinase (FAK), which is a non-receptor protein-tyrosine kinase (PTK).
Immunofluorescence and in vitro and in vivo assays show that FAK is co-localized at the
C-terminus of integrin receptors and the phosphorylation of FAK at various tyrosine
residues transduces signals downstream and causes activation of the MAPK cascade.
Seig et al. showed that platelet derived growth factor (PDGF) and epithelial growth factor
(EGF) stimulated cell migration requires integrin interaction with FAK intra-cellularly
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(116). Xiong et al. elucidated the ultrastructure of integrin αvβ3 with several EGF
domains and its unique folding (117).

1.7.1

Integrin αvβ3

Many studies demonstrated that the expression of αvβ3 promotes tumour cell adhesion,
migration and invasion in breast cancer, ovarian cancer, melanoma and glioma, (110,
118, 119, 120, 121, and 122). Several studies using various breast cancer cell lines
demonstrated that integrin activates MMP-9 in regulating the migration of metastatic
breast cancer cell lines and not pre-malignant cell lines (123). Utilizing a similar model
Naber showed that the activation of TGF-β can induce up-regulation of integrin β3 in
malignant but not pre-malignant cell lines via Src but not Smad (124). Recently,
overexpression of integrin αv in laryngeal SCC demonstrated more advanced stage,
higher histological grade and poorer clinical outcome and survival (125). However, there
are currently no studies on the expression of integrin in SG tumours nor its influence on
patient prognosis.

1.8 Summary
Numerous studies had shown that OPN interaction with CD44 facilitates further binding
to integrin αvβ3, and co-expression of these 3 markers had been shown to exhibit
advanced clinical disease, tumours metastasis and poorer prognosis and survival in
numerous tumours.
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Chapter 2

2

Hypothesis and Rationale

2.1 Hypothesis
In this study, we hypothesize:
1.

SG tumours will show increased levels of OPN, CD44, and integrin αvβ3
compared to normal SG tissues and these entities will be useful as biomarkers for
the diagnosis and/or prognosis of certain SG tumours;

2.

OPN levels will be positively correlated with CD44 and integrin αvβ3 levels in
malignant SG tumours; and

3.

OPN levels will show a positive correlation with clinical parameters of disease
and may have the potential to be a prognostic marker for SG tumours.

2.2 Rationale
Clinical management of individual patients with SG tumours is based solely on American
Joint Committee on Cancer (AJCC) TNM staging. However, this only provides the “best
guess” on the tumour’s aggressiveness and the final outcome of the disease. As such,
researchers and clinicians are in search of new diagnostic or prognostic markers that can
identify high risk patients who would benefit from adjuvant therapy and closer
monitoring. Improvement in the survival rates of all neoplasms requires an
understanding of the natural course of the disease, suitable screening and/or detection
tests, reliable prognostic indicators, and effective treatment options. Consequently, over
the past decade, significant efforts have been made to identify beneficial diagnostic and
prognostic tumour markers for SG neoplasms.
Research in the past decade has investigated the expression of OPN, CD44 and integrin
αvβ3 in normal SG and SG neoplasms. The expression of OPN and its receptors in tissues
such as the colon, breast and prostate has been monitored as biomarkers in corresponding
malignancies. This suggests a potential utility of the levels of OPN and its receptors, as a

28

prognostic tool for SG neoplasms. OPN has also been detected in saliva, and may
eventually provide a non-invasive alternative to biopsy in the diagnosis of SG neoplasms.

2.3 Aims and Objectives
This study aims to analyze the immunohistochemical (IHC) expression of OPN and its
receptors (CD44 and integrin αvβ3) in SG neoplasms. We aim to characterize the IHC
expression of OPN and its receptors in the cellular structure of normal SG tissues and in
the 5 types of SG neoplasms. In addition, the levels of IHC expression of OPN and its
receptors in normal SGs, a common benign SG neoplasm and malignant SG neoplasms
will be compared. Subsequently, IHC levels of OPN will be correlated with its receptors
and clinical parameters including: SG tissue type, patient age, patient gender and tumour
grade, to determine the presence or absence of a relationship that may predict patient
prognosis.
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Chapter 3

3

Method and Materials

3.1 Experimental Objectives
A. To examine the IHC profile of OPN, CD44 and integrin αvβ3 in normal salivary
gland, ACA, ACC, MEC, PA and PLGA tissues.
B. To examine the correlation between IHC expression of OPN, CD44 and integrin
αvβ3 in normal and neoplastic salivary gland tissues.
C. To examine the association between OPN, CD44 and integrin αvβ3 with various
clinical parameters.

3.2 Tissue Specimens
3.2.1

Tissue Criteria

Tumour samples were sourced from 1984 to 2008 for ACA and PLGA, while, mucocele,
ACC, MEC and PA samples were taken from the years 2000 to 2007. The pathological
diagnoses were based on the diagnostic criteria established by the World Health
Organization (WHO; Geneva, Switzerland) and the AFIP (Washingston, D.C., USA).

3.2.2

Normal Tissues

In order to obtain normal specimens to serve as negative controls for this experiment,
normal salivary gland tissue adjacent to mucoceles was used. Although, it is known that
OPN is expressed in lymphoid tissue during inflammation, there is no evidence to
indicate that such inflammation causes up-regulation of OPN expression in
morphologically normal epithelial salivary gland tissue at a distance from the
inflammatory process.
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3.2.3

Inclusion Criteria
Primary diagnosis of mucocele, PA, ACC, ACA, PLGA, and MEC

3.2.4

Exclusion Criteria
Revision of primary diagnosis
Unavailable tissue blocks
Inadequate tissue within the paraffin blocks
Pathology from the same patient

3.2.5

Specimens

A total of 126 specimens were located in the oral pathology database at the initial stage of
gathering samples (Normal N = 20, PA N = 21, MEC N = 34, ACC N = 22, ACA N = 12,
and PLGA N = 17). Of those specimens: 1 PA, 2 MEC, and 1 PLGA had insufficient
tissue for our experiment; 2 ACA were two biopsies from the same patient at the same
site 4 months apart, (as such, only the initial biopsy block from that patient was used for
the 2 ACA samples) and finally 3 listed MEC tissue blocks were not available. A final
number of 118 specimens were used for these experiments. These specimens included
mucocele (used as control, N = 20), ACA (N = 11), ACC (N = 22), MEC (N = 29), PA
(N = 20), and PLGA (N = 16).

3.3 Assay Methods
3.3.1

Antibody selection

The primary antibodies used in this study were commercially available. All of the
antibodies used were monoclonal mouse anti-human antibodies. The OPN antibody with
affinity to RGD domain was purchased from Assay Designs Inc. (MI, USA). The CD44
antibody with affinity to epitope 1 (pan-isoform) was purchased from BD pharmingen
(BD biosciences, NJ, USA). Finally, the integrin αvβ3 antibody with an affinity to the vβ3
region was purchased from AbCAM Inc. (MA, USA). Replacement of primary
antibodies with non-immune serum completely eliminated the immunostaining in all
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tissues examined. This indicated that the antibodies were specific for their respective
protein and that the staining protocol was effective.

3.3.2

Immunohistochemistry

A standard immunoperoxidase staining method was used to localize the expression of
OPN, CD44 and integrin αvβ3 in NSGs, PAs, ACAs, ACCs, MECs, and PLGAs. The
sensitivity of the reaction was controlled with known reactive tissues such as
macrophages from mucoceles, the tonsil, and multinucleated giant cells from peripheral
giant cell granulomas as positive controls for OPN, CD44 and integrin αvβ3, respectively.
Negative controls for this experiment were based on the manufacturers’ information
package for the isoform such as IgG1 for OPN and integrin and IgG2 for CD44. Aside
from the primary antibodies which were omitted, the negative controls received the same
experimental protocol. Pilot experiments and serial dilutions were conducted to optimize
each antibody used.
Five µm thick serial sections were cut from each formalin fixed paraffin embedded tissue
block using a microtome (Microm HM 325; GMI Inc., Ramsey, MN, USA), specimens
were then transferred to a 37◦C water bath to allow relaxation of each section. Specimens
were mounted onto positively charged microscopic slides and dried in an incubating oven
at 37◦C overnight.
All tissue specimens underwent deparaffinization and rehydration by immersing the
specimens in a series of solutions as follows: 3 changes of Xylene for 5 minutes, 2
changes of 100% ethanol for 2 minutes, 2 changes of 95% ethanol for 2 minutes, 2
minutes in 70% ethanol, and 2 minutes in distilled water. Specimens were quenched in a
freshly prepared solution of 3% hydrogen peroxide in methanol for 5 minutes and then
rinsed with distilled water and 99% PBS on a shaker for 5 minutes each.
For OPN and integrin αvβ3, tissue sections were subject to an antigen retrieval process in
citrate buffer, pH at 6.00, boiling to 125◦C in a pressurized de-cloaking chamber at
approximately 25 kPa. These sections were rinsed with running tap water and washed
with PBS for 5 minutes each. For CD44, antigen retrieval steps were not performed, as
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determined during the pilot experiment, which showed excessive background staining at
very low concentrations of CD44 antibody with citrate buffer antigen retrieval.
All tissue sections were treated with 10% horse serum at room temperature for 30
minutes. Primary monoclonal mouse anti-human antibodies (OPN, CD44 and integrin
αvβ3) at a predetermined titre were applied (Please refer to the results section for detail
titre dilutions). OPN and integrin samples were incubated overnight at 4◦C, while CD44
samples were incubated for 1 hour at room temperature. Excess antibodies were washed
off twice with PBS for 5 minutes. Samples were then incubated with anti-mouse
immunoglobulin conjugated with horse radish peroxidase micro polymers (ImmPRESS®
Reagent Kit; Vector laboratories, Burlingame, CA, USA) for 30 minutes at room
temperature in a humidified chamber. Excess secondary antibodies were washed off
twice with PBS for 5 minutes. The enzymatic reaction took place in a freshly prepared
3,3’-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich, Oakville, ON, CAN)
solution (for integrin, nickel was added to the DAB solution) for 10 minutes at room
temperature. Specimens were rinsed with distilled water and counterstained with Harris’
Hematoxylin. Then the specimens were dehydrated through a series of progressively
concentrated EtOH solutions; 70% for 2 minutes, 95% twice for 2 minutes and 100%
twice for 2 minutes. Afterwards, the slides were cleared thrice in Xylene solution for 3
minutes each time and then mounted and cover-slipped in Cytoseal® permount.

3.4 Data collection and analysis
3.4.1

Scoring Criteria

Under light microscopy, staining was visualized and assessed using a well-documented
semi-quantitative method (126, and 127). A score, ranging from 0 to 3 (0: no staining, 1:
mild staining, 2: moderate staining, and 3: intense staining), was given to the intensity of
the staining plus an estimated fraction of positively stained normal glands or tumour cells
were scored from 0 to 5 (0: staining, 1: < 1% of cells, 2: 1 to 10% of cells, 3: 10 to 33%
of cells, 4: 33 to 66% of cells, and 5: > 66% of cells). The overall staining was then
expressed as a single composite score, which is the sum of the proportion and intensity
scores (0 = negative staining and 2 to 8 for positive staining).
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The average composite score for each primary antibody in normal salivary glands and
tumour tissues was compared. In normal salivary glands, ductal and acinar cells (nonductal) were assessed separately. In pleomorphic adenomas, adenoid cystic carcinomas,
and polymorphous low grade adenocarcinomas, both ductal and non-ductal cells were
scored. Ductal structures are those cells that line the lumen of ducts or duct-like
structures within a tumour, whereas non-ductal structures are any cells in the tumour
tissues that are not lining ducts or duct-like structures. In mucoepidermoid carcinomas,
there are no ductal or non-ductal components; rather it is classified as squamous,
intermediate or mucous cells. In acinic cell adenocarcinomas, there are only non-ductal
structures within the tumour tissues. For normal salivary glands, PA, ACC and PLGA
tissues, the average of the OPN, CD44 and integrin αvβ3 composite scores in ductal and
non-ductal tissues were calculated for each case. The final composite scores were
expressed as the median of the composite scores for all cases per tissue type. For MEC,
the score for each antibody for the 3 cell types per case was calculated then the final
composite score for each of the antibodies in MEC was given as the median composite
score for all MEC cases. For ACA, the non-ductal cell scores were calculated for each
case for each antibody and then the median composite scores were computed for all ACA
cases. Staining was assessed by three examiners to achieve consistency of scoring.

3.4.2

Statistical analysis

Assistance for the statistical analysis of the results of this study was provided by the
Department of Epidemiology and Biostatistics at the University of Western Ontario. The
statistical analysis of the data was divided into three parts: 1) the comparison of the
immunoexpression of various antibodies in normal and neoplastic tissues, 2) the
correlation of immunoexpression between OPN, CD44 and integrin αvβ3 in normal and
neoplastic tissues, and 3) the association between immunoexpression and various clinical
parameters. Throughout the study, the immunoexpression levels were calculated as a
median composite score for all patients for each of the following: OPN, CD44 and
integrin αvβ3. Composite scores were used to test for statistical significance. Due to the
ordinal nature of the composite scores, it could not be assumed that they are continuous
and normally distributed. Thus, non-parametric statistics were used to analyse the data.
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The first part of the statistical analysis, the expression profile of OPN, CD44 and integrin
αvβ3 was analysed in normal salivary glands and salivary gland tumours. Each tumour
group was treated individually as an independent group. The non-parametric MannWhitney U test (Wilcoxon signed-rank test) was used to compare the median IHC
expressions of OPN, CD44 and integrin αvβ3 levels in ACAs, ACCs, MECs, PLGAs and
PAs with NSGs. The Bonferroni correction was applied to the alpha level (0.05). The
adjusted alpha level and a two-tailed p-value < (0.05/5 = 0.01) was considered
statistically significant throughout this part of the analysis. The Kruskal-Willis test was
used to ensure that the Bonferroni correction was not too conservative. The median and
interquartile ranges for the expression levels of OPN, CD44 and integrin αvβ3 were
reported.
The second part of the analysis involved the association study of immunoexpression of
OPN to CD44 and integrin αvβ3 in all tissue groups. The correlation between proteins of
interest in all 6 groups (NSG, PA, MEC, ACA, ACC, and PLGA) was tested using nonparametric Spearman’s rank correlation test and a correlation coefficient was calculated.
The third part of the analysis involved the test for clinical association. In this analysis,
both normal and PA cases were excluded. In addition, ACA, PLGA cases were excluded
in the clinical parameter of histological grade, because all ACA and PLGA were low
grade variants, thus, no correlation value was calculated. For all other clinical
parameters, all malignant salivary gland tumours were included. This was performed by
comparing the median OPN, CD44 and integrin αvβ3 composite scores in a binary fashion
of the clinical parameters using Mann-Whitney-U test with an alpha of 0.05 as follows:
1) low grade vs. intermediate/high grade, 2) males vs. females, and 3) major vs. minor
salivary glands. Furthermore, Spearman’s rank correlation test was used to determine a
correlation coefficient for each OPN, CD44 and integrin αvβ3 for clinical grade.
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Chapter 4

4

Results

4.1 Patient demographics
Patient ages at the time of diagnosis ranged from: 5 to 77 years of age for mucoceles
(NSGs), 14 to 80 years for PAs, 53 to 88 years for ACAs, 40 to 80 years for ACCs, 15 to
88 years for MECs, and 17 to 91 years for PLGAs; with a mean age at presentation of
34.2 ± 22.0, 44.1 ± 18.8, 65.7 ± 17.9, 55.9 ± 12.8, 53.7 ± 20.0, and 65.1 ± 9.5 years,
respectively.
For the association study, only data from malignant tumours was used. Clinical
parameters obtained from medical charts included: age, gender, tumour type, type of
salivary gland, and histological grade (tables 4.1 – 4.6).

4.2 Antibody titers
Before commencing the IHC staining of salivary gland tissues for OPN, CD44 and
integrin αvβ3, an optimal titer for each of the above antibodies needed to be determined.
Using the known positive control specimens based on the recommendations from the
antibodies’ manufacturers for each of the antibodies, the following titers were screened:
(1) OPN (1mg/ml): 1/100, 1/200, 1/300 and 1/400 in 4°C with overnight incubation, (2)
CD44 (1mg/ml): 1/100, 1/200, 1/400 and 1/800 with 1 hour incubation at room
temperature, and (3) Integrin αvβ3 (1mg/ml): 1/10, 1/20, 1/25 and 1/50 with overnight
incubation at 4°C.
OPN at 1/100, 1/200 and 1/300 dilution showed intense staining within the cytoplasm of
macrophages, and, significant background staining of epithelial cells at 1/100 and 1/200
dilution, but background staining was not noticeable at 1/300 concentration. At the 1/400
titer, areas of weak or no staining were observed (figure 4.1).
CD44 at 1/100, 1/200 and 1/400 demonstrated membranous staining. However, at low
titers (1/100 and 1/200) there was significant background staining, and overflowing into
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Patient

Age

Gender

Location

Grade

1

27

F

Lower lip

N/A

2

19

M

Lower lip

N/A

3

41

M

Lower lip

N/A

4

39

M

Lower lip

N/A

5

12

M

Lower lip

N/A

6

11

F

Lower lip

N/A

7

48

F

Lower lip

N/A

8

77

M

Buccal mucosa

N/A

9

5

F

Lower lip

N/A

10

10

F

Lower lip

N/A

11

75

F

Floor of mouth

N/A

12

41

F

Lower lip

N/A

13

36

F

Hard palate

N/A

14

22

M

Soft palate

N/A

15

63

M

Hard palate

N/A

16

45

M

Lower lip

N/A

17

37

F

Lower lip

N/A

18

54

F

Lower lip

N/A

19

7

M

Lower lip

N/A

20

15

M

Lower lip

N/A

Average (SD)

34.2(22.0)

M:F (1:1)

Table 4-1 Patients’ demographics for the mucocele (NSG) group
F – Female, M- Male, N/A – not applicable, SD – Standard Deviation
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Patient

Age

Gender

Location

Grade

1

44

F

Parotid

N/A

2

34

F

Parotid

N/A

3

42

F

Parotid

N/A

4

28

F

Upper lip

N/A

5

30

F

Upper lip

N/A

6

80

M

Soft palate

N/A

7

50

F

Upper lip

N/A

8

76

F

Buccal mucosa

N/A

9

14

M

Upper lip

N/A

10

50

M

Parotid

N/A

11

80

M

Hard palate

N/A

12

26

F

Hard palate

N/A

13

50

F

Upper lip

N/A

14

15

F

Soft palate

N/A

15

44

M

Hard palate

N/A

16

39

M

Hard palate

N/A

17

46

F

Upper lip

N/A

18

31

M

Maxillary

N/A

tuberosity
19

46

F

Soft palate

N/A

20

56

F

Hard palate

N/A

Average (SD)

44.1(18.8)

M:F (1:1.8)

Table 4-2 Patients’ demographics for the PA group
F – Female, M – Male, N/A – Not applicable, SD – Standard deviation

38

Patient

Age

Gender

Location

Grade

1

79

F

Buccal mucosa

Low

2

55

M

Buccal mucosa

Low

3

59

M

Floor of mouth

Low

4

44

F

Buccal mucosa

Low

5

57

F

Soft palate

Intermediate

6

67

F

Buccal mucosa

Low

7

59

F

Lower lip

Low

8

58

F

Retromolar pad

Low

9

40

M

Retromolar pad

Low

10

70

M

Buccal mucosa

Low

11

55

M

Retromolar pad

Low

12

71

F

Lower lip

High

13

45

M

Soft palate

Intermediate

14

26

F

Hard palate

Low

15

15

F

Soft palate

Low

16

41

M

Soft palate

Intermediate

17

79

M

Hard palate

Intermediate

18

29

F

Hard palate

Intermediate

19

37

M

Buccal mucosa

Intermediate

20

57

M

Soft palate

Intermediate

21

33

M

Hard Palate

Intermediate

22

27

M

Retromolar pad

Low

23

88

M

Hard palate

Low

24

54

F

Hard palate

Intermediate

25

56

F

Soft palate

Intermediate

26

79

M

Hard palate

Intermediate

27

57

F

Hard palate

Intermediate

28

62

M

Parotid

Low

39

29

63

F

Average (SD)

53.9(17.9)

M:F (1:1.22)

Lower Lip

Table 4-3 Patients’ demographics for the MEC group
F – Female, M – Male, SD – Standard deviation

Low

40

Patient

Age

Gender

Location

Grade

1

67

M

Hard palate

High

2

76

M

Soft palate

Low

3

57

M

Buccal mucosa

Intermediate

4

48

F

Oral mucosa

Low

5

40

M

Hard palate

Intermediate

6

44

F

Hard palate

Low

7

67

F

Hard palate

Low

8

45

F

Upper lip

Low

9

53

M

Buccal mucosa

Low

10

54

F

Hard palate

Low

11

80

M

Buccal mucosa

Intermediate

12

55

M

Hard palate

Intermediate

13

45

F

Hard palate

Intermediate

14

75

M

Hard palate

Intermediate

15

75

M

Parotid

Intermediate

16

53

F

Buccal Mucosa

High

17

73

F

Left Maxilla

High

18

75

M

Hard palate

High

19

70

F

Maxillary Sinus Low

20

67

F

Floor of mouth

High

21

77

F

Buccal mucosa

Low

22

53

F

Floor of mouth

Intermediate

Average (SD)

61.3(12.8)

M:F (1:1.2)

Table 4-4 Patients’ demographics for the ACC group
F – Female, M – Male, SD – Standard deviation

41

Patient

Age

Gender

Location

Grade

1

77

F

Buccal mucosa

Low

2

78

M

Hard palate

Low

3

78

M

Hard palate

Low

4

83

F

Buccal

Low

vestibule
5

63

M

Hard palate

Low

6

91

M

Maxillary

Low

tuberosity
7

59

F

Soft palate

Low

8

46

M

Buccal mucosa

Low

9

17

M

Hard palate

Low

10

38

M

Buccal mucosa

Low

11

67

F

Upper lip

Low

12

61

F

Soft palate

Low

13

86

M

Buccal mucosa

Low

14

56

M

Hard palate

Low

15

76

F

Soft palate

Low

16

Unavailable

F

Buccal mucosa

Low

Average (SD)

65.1(20.0)

M:F (1:0.8)

Table 4-5 Patients’ demographics for the PLGA group
F – Female, M – Male, SD – Standard deviation

42

Patient

Age

Gender

Location

Grade

1

77

F

Soft palate

Low

2

67

M

Upper lip

Low

3

68

M

Retromolar pad

Low

4

59

M

Upper lip

Low

5

67

M

Parotid

Low

6

88

M

Parotid

Low

7

68

M

Parotid

Low

8

68

M

Submandibular

Low

9

60

M

Parotid

Low

10

53

M

Parotid

Low

11

59

F

Parotid

Low

Average (SD)

66.7 (9.5)

M:F (1:0.23)

Table 4-6 Patients’ demographics for the ACA group
F – Female, M – Male, SD – Standard deviation
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A.

B.

C.

D.

E.
Figure 4-1 Serial dilutions of anti OPN antibodies for IHC staining of mucocele
(NSG) control at 200x original magnification.
A. Negative control (No antibody) showed no staining. B. OPN IHC staining at 1/100
concentration. C. OPN IHC staining at 1/200 concentration. Note that at both
concentrations, there was excessive staining of both nuclei and cytoplasm, with staining
in fibroblasts in the connective tissue. D. OPN IHC staining at 1/ 300 concentration with
good differentiation of nuclei and cytoplasm without staining of fibroblasts. E. OPN
IHC staining at 1/400 concentration showed inconsistent staining of inflammatory cells
within the lesion.

44

A.

B.

C.

D.

E.
Figure 4-2 Serial dilutions of IHC staining for CD44 on tonsillar tissue at 200x
original magnification.
A. Negative control (no antibody) for CD44 with IgG2. B. CD44 IHC staining at 1/100
concentration showed intense membranous staining of lymphocytes. C. CD44 IHC
staining at 1/200 concentration showed a moderate membranous staining of lymphocytes.
D. CD44 IHC staining at 1/400 concentration showed membranous staining without
excessive overstaining of lymphocytes. E. CD44 IHC staining at 1/800 concentration
showed inconsistent staining.
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A.

B.

C.

D.

E.
Figure 4-3 Serial dilutions of IHC staining for integrin αvβ3 on a peripheral giant
cell granuloma (PGCG) at 200x original magnification.
A. Negative control (no antibody). B. Integrin αvβ3 IHC staining at 1/10 concentration
showing membranous staining of multinucleated giant cells. C. Integrin αvβ3 IHC
staining at 1/20 concentration. D. Integrin αvβ3 IHC staining at 1/25 concentration. E.
Integrin αvβ3 IHC staining at 1/50 concentration showed inconsistent membranous
staining of multinucleated giant cells.
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the cytoplasm was not detected at the 1/400 concentration. At 1/800, inconsistency of the
membranous staining occurred (figure 4.2).
Integrin αvβ3 at 1/10, 1/20 and 1/25 demonstrated well defined staining of the cellular
membrane of multi-nucleated giant cells. Even though no background staining or
overflowing occurred with all 3 dilutions, a 1/25 dilution was used for subsequent
experiments to preserve the amount of antibody used per experiment. At 1/50, staining
was weak (figure 4.3).

4.3 Localization and expression of all 3 markers in Salivary
Gland Tissues
4.3.1

Normal Saliva Gland - Mucocele (NSG)

An inflammatory infiltrate, mainly macrophages, surrounding the mucocele demonstrated
strong IHC staining of OPN in the cytoplasm and nucleus of macrophages. Adjacent
salivary gland tissue showed strong IHC staining of ductal cells and myoepithelial cells,
moderate IHC staining of acinar cells, and scant / faint IHC staining in mucous globules.
While there was moderate membranous IHC staining in ductal cells with CD44, there
was a lack of membranous staining at the luminal region of ductal cells. There was
intense staining of acinar cells with CD44. There was no staining of integrin αvβ3 in both
the ductal and acinar cells of SGs, but luminal staining of peri-lesional endothelial cells
was observed (figure 4-4).
The median scores of IHC staining for OPN, CD44 and integrin αvβ3 in the ductal and
acinar cells of NSGs are presented in figure 4-5. Both OPN and CD44 were expressed in
both ductal and acinar components of the NSG. OPN expression was higher in the ductal
cells (4 vs. 3, p < 0.001) while CD44 showed higher expression in the acinar cells (3 vs.
7, p <0.001). Integrin αvβ3 expression was not detected in either component of NSG, but
was detected in peri-lesional endothelial cells.

47

A.

B.

C.

D.

Figure 4-4 IHC staining of a NSG at 400x original magnification for OPN, CD44
and integrin αvβ3.
A. OPN demonstrated strong IHC staining in both cytoplasmic and nuclear regions, but a
scant amount of staining in the mucous globules. B. CD44 showed strong IHC staining
staini
within acinar cells, and mild to moderate staining in ductal cells with no luminal staining.
C. Integrin αvβ3 showed no IHC staining in either ductal or acinar cells. D.
D Integrin αvβ3
showed peri-lesional
lesional endothelial cells staining.
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Integrin

Figure 4-5 IHC staining score of all 3 markers in ductal and non
non-ductal
ductal components
of NSGs.
There was significantly higher OPN expression in the ductal component (4 vs. 3, p <
0.01), and higher CD44 expression in th
the non-ductal
ductal component (3 vs. 7, p < 0.01).
There was no detected expression of integrin αvβ3 in either component.
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4.3.2

Pleomorphic Adenoma (PA)

IHC OPN expression was found in neoplastic ductal and non-ductal cells, both of which
demonstrated moderate levels of staining. However, there was no IHC staining of the
myxoid / cartilaginous region of the lesion. IHC CD44 staining showed moderate
staining of non-ductal cells, and mild levels of membranous staining of ductal cells, but
there was a lack of luminal staining. There was a lack of integrin αvβ3 staining in both
ductal and non-ductal components in all PA samples (figure 4-6).
The median scores of IHC staining for OPN, CD44 and integrin αvβ3 in the ductal and
non-ductal cells of pleomorphic adenomas are presented in figure 4-7. OPN was
expressed in similar levels in both ductal and non-ductal cells (4 vs. 4, p = 0.288), while
CD44 showed increased expression in non-ductal cells compared to ductal cells (2 vs. 4,
p < 0.001). No expression of integrin αvβ3 was found in PA.
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A.

B.

C.
Figure 4-6 IHC staining of PA for OPN, CD44 and Integrin αvβ3 at 400x original
magnification.
A. OPN demonstrated moderate IHC staining in both cytoplasmic and nuclear regions. B.
CD44 showed moderate IHC staining in non-ductal cells, and mild staining in ductal cells
with no luminal staining. C. Integrin αvβ3 showed absence of IHC staining.
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Figure 4-7 IHC staining score of all 3 markers in ductal and non
of Pas.
There was no difference in OPN expression in both components (4 vs. 4, p = 0.29), while
significantly higher CD44 expression in the non
non-ductal
ductal component (2 vs. 4, p < 0.01).
There was no detected expression of integrin αvβ3 in both components.
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4.3.3

Mucoepidermoid Carcinoma (MEC)

OPN IHC staining demonstrated moderate staining of squamous cells compared to strong
staining of mucous and intermediate cells. There was uniform, moderate IHC staining of
CD44 on all neoplastic components of MEC. There was no consistent staining of
integrin αvβ3 in any MEC specimens, but scant amounts of IHC staining on mucous cells
of MEC were noted in several specimens (figure 4-8).
The median scores of IHC staining for OPN, CD44 and integrin αvβ3 in mucous,
intermediate and squamous cells of MECs are presented in figure 4-9. The general trend
was that all 3 markers demonstrated higher values in both mucous and intermediate cells
compared to squamous cells (OPN: mucous 6 vs. intermediate 6 vs. squamous 4, p >
0.05, and CD44: 5 vs. 4 vs. 4, p > 0.05). No detectable level of integrin αvβ3 was
recorded in squamous cells (2 vs. 0 vs. 0, p > 0.05).
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A.

B.

C.
Figure 4-8 IHC staining of MEC for OPN, CD44 and integrin αvβ3 at 400x original
magnification.
A. OPN demonstrated strong IHC staining in both cytoplasmic and nuclear regions of
mucous and intermediate cells. B. CD44 showed moderate IHC staining throughout the
tumour. C. Integrin αvβ3 showed scattered IHC staining with mucous cells.
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Figure 4-9 IHC staining score of all 3 markers in various non
non-ductal
ductal components of
MECs.
There were no significant differences in OPN, CD44 and integrin αvβ3 expression among
the various non-ductal
ductal components (6 vs. 6 vs. 4, p > 0.05), (5 vs. 4 vs. 4, p > 0.05), and
(2 vs. 0 vs. 0, p > 0.05).
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4.3.4

Adenoid Cystic Carcinoma (ACC)

IHC staining of OPN in ACC demonstrated moderate to strong expression in both the
cytoplasm and nucleus of both the ductal and non-ductal components of the lesion. It
highlighted peri-neural invasion and some staining into the nerve bundles was seen.
There was moderate membranous staining of CD44 in the non-ductal component, and
almost absent of membranous staining with a lack of luminal staining when staining was
presented in the ductal component. There was lack of integrin αvβ3 staining in all the
samples of ACC (figure 4-10).
The median scores of IHC staining for OPN, CD44 and integrin αvβ3 in ductal and nonductal cells of adenoid cystic carcinomas are presented in figure 4-11. OPN had similar
IHC scores in both the ductal and non-ductal components (4 vs. 4, p = 0.358), while
CD44 scores were lower in ductal than non-ductal components (0 vs. 4.5, p < 0.001).
There was no expression of integrin αvβ3 found in adenoid cystic carcinoma.
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A.

B.

C.
Figure 4-10 IHC staining of ACC for OPN, CD44, and integrin αvβ3 at 400x original
magnification.
A. OPN showed intense IHC staining throughout this example, B. CD44 showed intense
membranous IHC staining throughout the tumour in this example, and C. integrin αvβ3
demonstrated lack of IHC staining.
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Figure 4-11 IHC staining score of all 3 markers in ductal and non
components of ACCs.
There was no significant difference in OPN expression in both components (4 vs. 4, p =
0.36), while significantly higher CD44 expression in the non
non-ductal
ductal component (0 vs. 4.5,
p < 0.01). There was no detected expression of integrin αvβ3 in either component.
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4.3.5

Acinic Cell Adenocarcinoma (ACA)

There was strong OPN IHC staining of the serous acinar cells in both the nucleus and
cytoplasm. There was strong uniform membranous staining of serous acinar cells with
CD44. There was intense luminal or pseudo-luminal IHC staining of serous acinar cells
with integrin, however, not all tumour cells were stained with integrin αvβ3 (figure 4-12).
The median scores of IHC staining for OPN, CD44 and integrin αvβ3 in serous acinar
cells of acinic cell carcinomas are presented in figure 4-13. All 3 markers scored in the
moderate to high level in ACA.
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A.

B.

C.
Figure 4-12 IHC staining of ACA for OPN, CD44, and integrin αvβ3 at 400x original
magnification.

A. OPN showed moderate to strong IHC staining of serous acinar cells, B. CD44 showed
intense membranous IHC staining of the tumour, and C. integrin αvβ3 demonstrated
strong IHC staining of the luminal surface of serous acinar cells.
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Figure 4-13 IHC staining score of all 3 markers in ductal and non-ductal
components of ACAs.
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4.3.6

Polymorphous Low Grade Adenocarcinoma (PLGA)

There was strong OPN IHC staining of both ductal and non-ductal components of these
tumours. There was moderate uniform membranous staining of non-ductal cells, and
mild IHC staining of the ductal component but not at the luminal surface, with CD44.
There was 1 specimen that showed staining of the non-ductal component within the
tumour with integrin αvβ3 (figure 4-14).
The median scores for IHC staining of OPN, CD44 and integrin αvβ3 in ductal and nonductal cells of polymorphous low grade adenocarcinomas are presented in figure 4-15.
Both ductal and non-ductal components of PLGA had similar IHC scores (6 vs. 6, p = 1),
while, non-ductal components had higher IHC scores with CD44 (2 vs. 5.5, p < 0.001).
Only 1 specimen demonstrated scant integrin αvβ3 expression in the non-ductal cells.
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A.

B.

C.
Figure 4-14 IHC staining of PLGA for OPN, CD44, and integrin αvβ3 at 400x
original magnification.

A. OPN showed strong IHC staining throughout the tumour, B. CD44 showed moderate
membranous non-ductal IHC staining throughout this example, and C. integrin αvβ3
showed lack of IHC staining. Note some faint membranous staining of endothelial cells.
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Figure 4-15 IHC staining score of all 3 markers in ductal and non
components of PLGAs
There were no significant difference
differences in OPN expression in both components (6 vs. 6, p =
1), while significantly higher CD44 expression in the non
non-ductal
ductal component (2 vs. 5.5, p
< 0.01). There was no detected expression of integrin αvβ3 in both components.
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4.4 Comparison of all 3 cellular marker expressions (IHC)
across all SG groups
The IHC levels of OPN, CD44 and integrin αvβ3 in the SG tumours (PA, MEC, ACC,
PLGA and ACA) were measured. The comparison of the levels of expression of all 3
cellular markers in control and in each tumour type, separated into ductal and non-ductal
components, are presented in figures 4-16 – 4-21. The statistically significant differences
between NSG and tumour tissues were labeled.
OPN
The IHC staining levels for OPN were consistently moderate to high in both ductal and
non-ductal components in all selected malignant tumours (MEC, ACC, PLGA and ACA),
but only moderate in the benign tumour, PA. Levels in NSG were moderate to high
(figures 4-16, and 4-17). In a Kruskal-Wallis analysis, a comparison across all of the
groups, the ductal and non-ductal components showed statistically significant differences
(ductal, p = 0.0003 and non-ductal, p ‹ 0.0001).
The pairwise non-parametric comparison of staining levels of ductal components of NSG
with benign and malignant tumours showed only PLGA was statistically significantly
different (IHC: 6 vs. 4, p = 0.0008), while PA and ACC demonstrated no differences,
respectively (PA IHC: 4 vs. 4, p = 1.00 and ACC IHC: 4 vs. 4, p = 1.00) (figure 4-16).
The comparison of non-ductal components showed that expression of OPN was higher in
malignant tumours compared to NSG (MEC: p = 0.0001, ACC: p = 0.0004, PLGA: p ‹
0.0001 and ACA: p ‹ 0.0001), while no difference was demonstrated for the benign
tumour (IHC: 5 vs. 4, p = 0.9965) (figure 4-17).
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Figure 4-16 Comparison of OPN expression in ductal cells in selected salivary gland
tumours.
PLGA showed a higher expression compared to both NSG (p < 0.001) and PA (p <
0.001), but not ACC with NSG and PA.
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Figure 4-17 Comparison of OPN expression in non-ductal cells in selected salivary
gland tumours.
All malignant SG tumours demonstrated a significantly higher expression of OPN
compared to NSG and PA, with the exception of ACC with PA.
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CD44
The IHC staining levels for CD44 were consistently lower in both ductal and non-ductal
components in most tumours (PA, MEC, ACC and PLGA), but not in the non-ductal
component of ACA compared to NSG (figure 4-18, and 4-19). When all groups were
compared, the ductal and non-ductal components showed significant differences (ductal,
p ‹ 0.0001 and non-ductal, p ‹ 0.0001).
The pairwise non-parametric comparisons of the ductal components of NSG with all
selected tumours showed statistical significances (PA IHC: 2 vs. 3, p ‹ 0.0001, ACC IHC:
0 vs. 3, p ‹ 0.0001 and PLGA IHC: 2 vs. 3, p = 0.0032) (figure 4-18).
The comparison of non-ductal components showed that expression of CD44 was lower in
most tumours compared to NSG (PA: p ‹ 0.0001, MEC: p ‹ 0.0001, and ACC: p =
0.0006), while no difference was demonstrated for PLGA (IHC: 5.5 vs. 7, p = 0.2211)
and ACA (IHC: 8 vs. 7, p = 1.00) (figure 4-19).

68

4

IHC staining

3

3

2

2

2

1

0

0
NSG

PA

ACC

PLGA

Figure 4-18 CD44 expression in ductal cells of selected salivary gland tumours.
There were significant differences (loss of expression) between NSG with both benign
and malignant SG tumours (p < 0.001), while no differences were found when malignant
SG tumours were compared to PA.
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Figure 4-19 CD44 expression in non-ductal cells of selected salivary gland tumours.
There were significant differences (loss of expression) between NSG with both benign
and malignant SG tumours (p < 0.001), with the exception of PLGA (p = 0.221) and
ACA (p = 1.0).
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Integrin αvβ3
No IHC staining for integrin αvβ3 was found in ductal components, while only mucous
and intermediate cells of MEC, non-ductal cells of PLGA and ACA expressed integrin
αvβ3 (figure 4-20, and 4-21). In the all group comparison, the non-ductal components
demonstrated statistically significant differences (p ‹ 0.0001).
Only pairwise comparisons of non-ductal components could be analysed. Only serous
cells of ACA showed statistical significance when compared to NSG (ACA IHC: 5.5 vs.
0, p ‹ 0.0001) (figure 4-21).
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Figure 4-20 Integrin αvβ3 expression in ductal cells of salivary gland tumours.
There was no expression of integrin αvβ3 noted in any ductal cells of the selected salivary
gland tumours.
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Figure 4-21 Integrin αvβ3 expression in non-ductal cells of selected salivary gland
tumours.
There was significant expression of integrin αvβ3 only in ACA.
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4.5 Association studies between OPN, CD44 and integrin
αvβ3 in all SG tumours
The co-expression of all 3 markers in all SG tissues studied showed parallel patterns of
OPN, CD44, and integrin αvβ3 (when expressed) IHC expression in myoepithelial derived
SG neoplasms (PA, ACC, and PLGA), but not non-ductal derived SG neoplasms (ACA
and MEC) (figure 4-22). Integrin αvβ3 expressed in MEC, ACA and PLGA allowed us to
explore a correlation of all 3 studied markers in these SG tumours, however, it
demonstrated no correlation with OPN nor CD44.
In NSG, there is a mild positive trend or correlation between OPN and CD44 but it is not
statistically significance. Mild negative but not significant correlations were found
between OPN and CD44 with PA and ACC. However, because there were no detectable
levels of integrin αvβ3 expressed in these 2 types of SG tissues (PA and ACC), no
correlation studies were analyzed (tables 4-7 to 4-9).
In the remaining 3 malignant SG tumours (ACA, MEC, and PLGA), there was expression
of integrin αvβ3 in some of the tumours, however, there were no statistically significant
correlations between integrin αvβ3 expression with either OPN or CD44 (tables 4-10 to 412). When comparing between OPN and CD44, only PLGA showed a moderate to high
significant positive correlation between OPN and CD44 IHC expression (r = 0.66, p =
0.0051).

74

Total Expression of all 3 markers
8
7

IHC Staining Score

6
5
OPN
4

CD44
Integrin αvβ3

3
2
1
0
NSG

PA

ACC

PLGA

ACA

MEC

Figure 4-22 IHC expression of all 3 markers in all selected salivary gland tumours.
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NSG

CD44

Integrin αvβ3

OPN

0.14 (0.547)

N/A
N/A

CD44

Table 4-7 Association among IHC levels of OPN, CD44 and integrin αvβ3 in normal
SGs as determined by Spearman’s correlation coefficient (r value) and p values in
brackets.

PA

CD44

Integrin αvβ3

OPN

-0.07 (0.761)

N/A
N/A

CD44

Table 4-8 Association among IHC levels of OPN, CD44 and integrin αvβ3 in PAs as
determined by Spearman’s correlation coefficient (r value) and p values in brackets.

ACC

CD44

Integrin αvβ3

OPN

-0.24 (0.289)

N/A

CD44

N/A

Table 4-9 Association among IHC levels of OPN, CD44 and integrin αvβ3 in ACCs as
determined by Spearman’s correlation coefficient (r value) and p values in brackets.
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MEC

CD44

Integrin αvβ3

OPN

0.27 (0.162)

0.19 (0.321)
0.07 (0.722)

CD44

Table 4-10 Association among IHC levels of OPN, CD44 and integrin αvβ3 in MECs
as determined by Spearman’s correlation coefficient (r value) and p values in
brackets.
PLGA

CD44

Integrin αvβ3

OPN

0.66 (0.005)*

0.31 (0.238)
0.42 (0.103)

CD44
Table 4-11 Association among IHC levels of OPN, CD44 and integrin αvβ3 in PLGAs
as determined by Spearman’s correlation coefficient (r value) and p values in
brackets.
•

Significant at p ≤ 0.05

ACA

CD44

Integrin αvβ3

OPN

-0.46 (0.185)

-0.27 (0.451)

CD44

0.19 (0.600)

Table 4-12 Association among IHC levels of OPN, CD44 and integrin αvβ3 in ACAs
as determined by Spearman’s correlation coefficient (r value) and p values in
brackets.
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4.6 Correlation between age and expression of all 3
markers in each SG tumour type
In the NSG tissues, the age of the patients ranged from 5 to 77. There were no specific
trends associated with OPN, CD44 and integrin αvβ3 and the age of the patients (figure 423). The correlation ranged from R = -0.01 to 0.14 (p > 0.05) for OPN, R = -0.08 to 0.02
(p > 0.05) for CD44 and there was no data for integrin αvβ3 because there were no
observable expression of integrin in NSG (table 4-13).
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A.

B.

79

C.
Figure 4-23 Correlation between age of patient with expression of OPN, CD44 and
integrin αvβ3 in normal salivary gland
A. OPN, showed no correlations between age of patients and both ductal and acinar
component. B. CD44, showed no correlations between age of patients and both ductal
and acinar component. C. integrin αvβ3, showed no correlations between age of patients
and both ductal and acinar component.
NSG

Ductal

Non Ductal

Total

OPN

0.14 (0.550)

-0.01 (0.973)

0.08 (0.723)

CD44

0.02 (0.924)

-0.08 (0.753)

-0.07
0.07 (0.773)

Integrin αvβ3

N/A

N/A

N/A

Table 4-13 Association between patient’s age in NSG with IHC levels of OPN, CD44
and integrin αvβ3 as determined by Spearman’s correlation coefficient (r value) and
p value in brackets
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Benign Tumour
In PA, the age of the patients ranged from 14 to 80. There was a slight upward trend for
OPN expression in ductal cells, but an opposite trend with non-ductal cells was noted.
However, overall there was no association with the age of the patient for PA and OPN,
CD44 and integrin αvβ3 expression (figure 4-24). The correlation ranged from R = -0.21
to 0.20 (p > 0.05) for OPN, R = -0.03 to 0.06 (p > 0.05) for CD44. Integrin αvβ3 was not
observed in PA (table 4-14).
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B.
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C.
Figure 4-24 Correlation between age of patients with expression of OPN, CD44 and
integrin αvβ3 in PA
non
A. OPN, showed no correlations between age of patients and both ductal and non-ductal
component. B. CD44, showed no correlations between age of patients and both ductal
and non-ductal
ductal component. C. integrin αvβ3, showed no correlations between age of
patients and both ductal and non
non-ductal component.
PA

Ductal

Non Ductal

Total

OPN

0.20 (0.388)

-0.21 (0.384)

0.11 (0.651)

CD44

0.06 (0.795)

-0.03 (0.895)

0.06 (0.807)

Integrin αvβ3

N/A

N/A

N/A

Table 4-14 Association between patient’s age in PA with IHC levels of OPN, CD44
and integrin αvβ3 as determined by Spearman’s correlation coefficient (r value) and
p value in brackets.
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Malignant Tumours
In MEC, patients’ ages ranged from 15 to 88. There was a general negative trend
towards OPN expression and age, while no trend existed for both CD44 and integrin αvβ3
and the patients’ ages (figure 4-25). The correlation ranged from R = -0.42 to -0.22 (p >
0.05) for OPN, except for intermediate cells (R = -0.42, p = 0.025), for CD44 R = -0.04
to 0.10 (p > 0.05) and for integrin αvβ3 R = -0.19 to -0.03 (p > 0.05) where no value was
obtained for squamous cells (table 4-15).
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C.
Figure 4-25 Correlation between ages of patients with expression of OPN, CD44 and
integrin αvβ3 in MEC
A. OPN showed a minimal negative correlation between ages of patients to mucous,
intermediate and squamous cells. B. CD44 showed a minimal positive correlation
between
een ages of patients to mucous, intermediate and squamous cells. C. Integrin αvβ3
showed no to minimal negative correlations with age of patients.
MEC

Mucous

Intermediate

Squamous

Total

OPN

-0.22
0.22 (0.256)

-0.42 (0.025)*

-0.33 (0.077)

-0.32 (0.092)

CD44

0.05 (0.812)

0.10 (0.609)

-0.04 (0.844)

0.08 (0.698)

Integrin αvβ3

-0.03
0.03 (0.858)

-0.19 (0.324)

N/A

-0.04 (0.835)

Table 4-15 Association between patient’s age in MEC with IHC levels of OPN, CD44
and integrin αvβ3 as determined by Spearman’s correlation coefficient (r value) and
p value in brackets.
•

Significant at p ≤ 0.05
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In ACC, the age of the patients ranged from 40 to 80. There was no specific trend
associated with OPN, CD44 and integrin αvβ3 and the patient age (figure 4-26). The
correlation ranged from R = 0 to 0.12 (p > 0.05) for OPN, R = -0.05 to 0.11 (p > 0.05) for
CD44, and no data for integrin αvβ3 was possible as no expression was observed in ACC
(table 4-16).
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CD44 IHC Scores
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8
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6
Linear (ACC CD44 Ductal)
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Linear (ACC CD44 NonNon
Ductal)
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Linear (ACC CD44 Total)
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Figure 4-26 Correlation between age of patients with expression of OPN, CD44 and
integrin αvβ3 in ACC
non
A. OPN showed no correlations between age of patients and both ductal and non-ductal
component. B. CD44 showed no correlations bet
between
ween age of patients and both ductal
and non-ductal
ductal component. C. Integrin αvβ3 showed no correlations between age of
patients and both ductal and non
non-ductal component.
ACC

Ductal

Non-Ductal

Total

OPN

0.12 (0.617)

0.00 (0.991)

0.06 (0.799)

CD44

-0.05
0.05 (0.827)

0.11 (0.650)

0.06 (0.795)

Integrin αvβ3

N/A

N/A

N/A

Table 4-16 Association between patient’s age in ACC with IHC levels of OPN, CD44
and integrin αvβ3 as determined by Spearman’s correlation coefficient (r value) and
p value in brackets
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The age of the patients, diagnosed with PLGA ranged from 17 to 91. There was a slight
negative trend towards OPN and no specific trend with integrin (figure 4-27). There was
a statistically significant moderate negative correlation between the age of patients with
PLGA and CD44 expression levels in both the ductal cells (R = -0.53, p = 0.0423) and
the total (R = -0.53, p = 0.0421), but not with non-ductal cells (R = -0.45, p = 0.089). A
non-significant association was noted with both OPN and integrin αvβ3 expressions (table
4-17).
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Figure 4-27 Correlation between age of patients with expression of OPN, CD44 and
integrin αvβ3 in PLGA
A. OPN showed minimal negative correlations between age of patients and both ductal
and non-ductal
ductal component. B. CD44 showed moderate negative correlations between
age of patients and both ductal and non
non-ductal component. C. Integrin αvβ3 showed no
correlation
tion between age of patients and both ductal and non
non-ductal
ductal components.
PLGA

Ductal

Non-Ductal

Total

OPN

-0.21
0.21 (0.451)

-0.11 (0.698)

-0.17
0.17 (0.554)

CD44

-0.53
0.53 (0.042)
(0.042)*

-0.45 (0.089)

-0.53
0.53 (0.042)*
(0.042)

Integrin

N/A

-0.43 (0.107)

-0.43
0.43 (0.107)

Table 4-17 Association between patient’s age in PLGA with IHC levels of OPN,
CD44 and integrin αvβ3 as determined by Spearman’s correlation coefficient (r
value) and p value in brackets
•

Significant at p ≤ 0.05
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In ACA, patient ages ranged from 53 to 88. There was no specific trend for OPN and
integrin αvβ3 expression; however, there was a strong upward trend between CD44 and
the age of the patients (figure 4-28). There was a statistically significant correlation
between CD44 and age of patient with ACA (R = -0.83, p = 0.003), while non-significant
correlations were found for OPN (r = 0.02, p = 0.962) and integrin αvβ3 (r = -0.24, p =
0.502) (table 4-18).
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B.
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C.
Figure 4-28 Correlation between age of patients with expression of OPN, CD44 and
integrin αvβ3 in ACA
A. OPN showed minimal positive correlations between age of patients and serous acinar
cells. B. CD44 showed strong positive correl
correlations
ations between age of patients and serous
acinar cells. C. Integrin αvβ3 showed a moderate negative correlation with age of
patients.
ACA

Serous Acinar

OPN

0.02 (0.956)

CD44

0.83 (0.003)*

Integrin αvβ3

-0.24 (0.502)

Table 4-18 Association between patient’s age in ACA with IHC levels of OPN, CD44
and integrin αvβ3 as determined by Spearman’s correlation coefficient (r value) and
p value in brackets
•

Significant at p ≤ 0.05
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4.7 Correlation between patients’ gender and all 3 markers
in each SG tumour
In NSGs, IHC expression of OPN and CD44 was similar between genders, and the small
differences of expression were not statistically significant (figure 4-29). Because integrin
αvβ3 expression was not detected in NSGs comparison between genders was not possible.
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CD44 expression between gender in
NSG
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B.
Figure 4-29 IHC expression (median) between male and female in NSG
A. OPN (3.5 vs. 3.75, p = 0.459), and B. CD44 (5.0 vs. 5.5, p = 0.768).
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Benign Tumour
In PA, IHC expression of OPN and CD44 was similar between the two genders, and the
small differences of expression were not statistically significant (figure 4-30). Because
integrin αvβ3 expression was not detected in PA comparison between genders was not
possible.
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Figure 4-30 IHC expression (median) between male and female in PA
A. OPN (4.0 vs. 3.5, p = 0.293), and B. CD44 (3.0 vs. 3.0, p = 0.415).
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Malignant Tumours
In ACA, IHC expression of OPN, CD44 and integrin αvβ3 was similar between the two
genders, and the small differences of expression were not statistically significant (figure
4-31).
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Figure 4-31 IHC expression (median) between male and female in ACA
A. OPN expression (6.0 vs. 6.0, p = 0.818), B. CD44 expression (8.0 vs. 8.0, p = 0.382),
and C. Integrin αvβ3 expression (6.0 vs. 3.5, p = 0.109).
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In ACC, IHC expression of OPN and CD44 was similar between the two genders, and the
small differences of expression were not statistically significant (figure 4-32). Because
integrin αvβ3 expression was not detected in ACC comparison between genders was not
possible.
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Figure 4-32 IHC expression (median) between male and female in ACC
A. OPN expression (3.75 vs. 4.5, p = 0.298), and B. CD44 expression (3.25 vs. 2.0, p =
0.605).
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In MEC, IHC expression of OPN, CD44 and integrin αvβ3 was similar between the two
genders, and the small differences of expression were not statistically significant (figure
4-33).
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Figure 4-33 IHC expression (median) between male and female in MEC
A. OPN expression (5.3 vs. 5.2, p = 0.830), B. CD44 expression (4.0 vs. 4.5, p = 0.667),
and C. Integrin αvβ3 (0 vs. 0.7, p = 0.117).
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In PLGA, IHC expression of OPN and CD44 was similar between the two genders, and
the small differences of expression were not statistically significant (figure 4-34).
Because integrin αvβ3 expression was not detected in PLGA, therefore, comparison
between genders was not possible.
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Figure 4-34 IHC expression (median) between male and female in PLGA
A. OPN expression (6.0 vs. 6.0, p = 0.877), B. CD44 expression (3.5 vs. 3.5, p = 0.959),
and C. Integrin αvβ3 expression (0 vs. 0, p = 0.719).
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4.8 Correlation between type of salivary gland (major vs.
minor) with all 3 markers in each SG tumour type
In this study, some of the selected tumours were from minor SGs only; therefore, a
comparison between major and minor SGs was not possible for NSG, ACC and PLGA.
In PA, there was no expression of integrin αvβ3, thus only OPN and CD44 were
compared, which showed no different in expression level for either marker between
major and minor salivary glands (figure 4-35).
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Figure 4-35 IHC expression (median) between major and minor SGs in PA
A. OPN expression (3.75 vs. 3.75, p = 0.785), and B. CD44 expression (3.0 vs. 2.75, p =
0.928).
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In ACA, no significant difference was detected between major and minor SGs for the
expression of OPN, CD44 and integrin αvβ3 (figure 4-36).
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Integrin αvβ3 expression between
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Figure 4-36 IHC expression (median) between major and minor SGs in ACA
A. OPN expression (6.0 vs. 6.5, p = 0.718), B. CD44 expression (8.0 vs. 8.0, p = 0.588),
and C. Integrin αvβ3 expression (5.0 vs. 6.0, p = 0.364).

107

In MEC, no significant difference was detected between major and minor SGs for the
expression of all 3 markers (figure 4-37).
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Integrin αvβ3 expression between
major and minor SGs in MEC
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Figure 4-37 IHC expression between major and minor SGs in MEC
A. OPN expression (4.5 vs. 3.2, p = 0.377), B. CD44 expression (3.0 vs. 4.5, p = 0.257),
and C. Integrin αvβ3 expression (0.7 vs. 0.3, p = 0.569).
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4.9 Correlation between all 3 markers and histological
grade of the selected malignant SG tumours
From this study, some of the selected tumours, such as PLGA and ACA, were all low
grade. Therefore, only MEC and ACC were analyzed and there were few specimens of
high grade tumours in both groups (1 of 29 in MEC and 4 of 22 in ACC). Consequently,
the high grade group was combined with the intermediate grade tumours for this analysis.
In MEC, there was a statistically significant mild to moderate positive correlation
between the grade of the tumour and OPN expression (r = 0.341, p = 0.044) (figure 4-38),
while a non-significant correlation was observed with both CD44 and integrin αvβ3 (table
4-19).
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Figure 4-38 OPN IHC staining comparing low grade versus intermediate/high grade
MEC

MEC

Tumour Grade

OPN

0.342 (0.044)*

CD44

0.253 (0.107)

Integrin αvβ3

0.171 (0.202)

Table 4-19 Association between tumour grade in MEC with IHC levels of OPN,
CD44 and integrin αvβ3 as determined by Spearman’s correlation coefficient (r
value) and p value in brackets
•

Significant at p ≤ 0.05
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In ACC, there was a statistically significant positive correlation between tumour grade
and OPN expression (r = 0.571, p = 0.013) (figure 4-39), while the correlation was nonsignificant with CD44 (table 4-20).
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Figure 4-39 OPN IHC staining comparing low grade versus intermediate/high grade
ACC

ACC

Tumour Grade

OPN

0.571 (0.013)*

CD44

0.159 (0.286)

Integrin αvβ3

N/A

Table 4-20 Association between tumour grade in ACC with IHC levels of OPN,
CD44 and integrin αvβ3 as determined by Spearman’s correlation coefficient (r
value) and p value in brackets
•

Significant at p ≤ 0.05
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4.10 Expression of OPN and integrin αvβ3 in endothelial
tissues
Integrin αvβ3 staining of endothelial cells was found in all specimens. However, not all
endothelial cells were positive for integrin αvβ3 IHC staining. Further examination found
that there was consistent integrin αvβ3 IHC staining (more than 66%) of subepithelial
endothelial cells in all samples (NSG, PA, ACA, ACC, MEC and PLGA) (Figure 4-40).
Moreover, only 33 – 66% of perilesional and the outer stromal endothelial cells showed
integrin αvβ3 expression (Figure 4-41), while less than 10% of endothelial cells
demonstrated integrin αvβ3 IHC staining within the centre of stroma of the lesions (Figure
4-42).
OPN expression was found in all endothelial cells. (Figure 4-43).
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D.

E.

F.

Figure 4-40 Integrin αvβ3 IHC staining in sub-epithelial endothelial cells (original
magnification 200x)
There is moderate to intense membranous staining of superficial sub-epithelial
endothelial cells. However, the IHC staining decreases in deeper sub-epithelial
endothelial cells. A. NSG, B. PA, C. ACA, D. ACC, E. MEC, and F. PLGA.
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F.

Figure 4-41 Integrin αvβ3 IHC staining in peri-lesional endothelial cells (original
magnification 200x)
There is faint to moderate and scattered staining of endothelial cells adjacent to the lesion
and within the outer layer of the lesion. A. NSG, B. PA, C. ACA, D. ACC, E. MEC, and
F. PLGA.
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A.

B.

C.

D.

E.
Figure 4-42 Integrin αvβ3 IHC staining in endothelial cells within tumours (original
magnification 200x)
There is minimal to no IHC staining of endothelial cells within the tumours, with the
exception of ACA. A. PA, B. ACA, C. ACC, D. MEC, and E. PLGA.
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Figure 4-43 OPN IHC staining of endothelial cells (Original magnification 200x)
There is strong and consistent IHC staining of endothelial cells.
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Discussion

Several studies have utilized IHC, ELISA and/or RNA levels by PCR methods, to reveal
the presence of OPN, CD44 (and its variants) and various integrins in SGs at the protein
and nucleic acid level (25, 30, 128, and 129). Studies which have tracked the coexpression of OPN with CD44 and/or integrin αvβ3 in various non-salivary gland
tumours, demonstrated that upregulation of these cellular markers in concert is correlated
with a more aggressive clinical course and poorer prognosis (130, 131, and 132).
In our study, the mean age of diagnosis for PA was 44.1 with an almost 2:1 female
predilection. With MEC, the mean age was 53.9 with a slight female predilection. The
mean age for ACC was 61.3 with a slight female predilection. For PLGA it was 65.1
years of age with a slight male predilection. For ACA, the mean age was 66.7 with a
strong male predilection of an almost 4.5 to 1 ratio (Table 4.1.3 – 4.1.6). These data are
similar to that reported by the AFIP by Ellis (12) with the exception of ACA’s gender
predilection. In Ellis’ study, a large series of over ten thousand salivary gland tumours
showed that ACA had a 2 to 1 female to male ratio. Our study showed the opposite but
this disparity can be accounted for by our low sample number of 11 as compared to Ellis’
sample size of several hundred patients with ACA which captured a broader presentation
and thus is more representative of the actual prevalence (12).

5.1 OPN
Our study demonstrated the IHC expression pattern of OPN for NSG, PA, MEC, ACC,
PLGA, and ACA. A previous study by Darling et al. (30) similarly identified the IHC
expression pattern of OPN for NSG, PA, PLGA and ACC. Our study showed that OPN
was expressed in both ductal and non-ductal cells in normal, benign and malignant
salivary gland tissues. In NSG, there was more intense IHC staining in ductal cells
compared to non-ductal cells (figure 4-4). This is slightly different from the results
published by Darling et al.; one reason for this may have been that the ImmPress IHC kit
was used in our study, while the Dako kit was used in theirs. Another reason may be that
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our NSG sample came from histologically normal appearing tissue adjacent to
mucoceles, which are inflammatory lesions. As it has been shown that OPN is
upregulated in inflammatory reactions, it is possible that a “field effect” of increased
OPN from the mucocele caused an increased expression of OPN in the ductal cells of
NSG in our samples, even though, our analysis was based on morphologically normal,
non-inflamed salivary gland tissue samples. The origin of the NSG utilized in Darling’s
2006 study is unknown (30).
In PA, there was a moderate amount of IHC staining with both the ductal and non-ductal
cells, though a slightly more intense staining pattern was noted in ductal cells (figure 46). In ACC, there was a moderate amount of IHC staining occurring equally in both
ductal and non-ductal cells (figure 4-10). In PLGA, strong IHC staining was noted
equally in both ductal and non-ductal cells (figure 4-14). This study was the first to
characterize OPN IHC expression in both MEC and ACA. In MEC, there was strong to
moderate IHC staining in mucous, intermediate and squamous cells (figure 4-8). With
ACA, there was strong IHC staining in serous acinar cells (figure 4-12). It is of interest
that this study was not able to statistically differentiate the sub-type of SG malignancy
(ductal vs. non-ductal origin) based on OPN expression. However, there is a trend of
increased OPN expression in tumours which are largely non-ductal in origin, MEC and
ACA. It might be useful to analysis a large sample size to determine if OPN has the
potential to differential various SG malignancies.
When comparing the IHC staining of OPN in ductal and non-ductal cells of various
salivary gland pathologies, our data showed significantly increased OPN expression in
both components in malignant SG tumours. In benign SG tumours and NSG, there was
no difference in OPN staining in ductal versus non-ductal cells. Although, our study is
descriptive in nature, it echoes the results of numerous studies on OPN upregulation
which noted increased expression in malignancy (130, 131, and 132). Given the low
incidences of SG malignancies, it would not be a useful screening tool for SG
malignancies. Yet, it may be useful as a diagnostic marker for SG malignancies.
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An interesting observation about ACC was noted in this study. ACC can be considered
the most aggressive in this group of malignant SG tumours because of its high propensity
for neural invasion at the time of diagnosis and its overall poor long term survival rate of
less than 40% in 20 years (1). However, although this finding was not statistically
significant, this study found that ACC’s OPN expression was the lowest compared to
other less aggressive SG tumours such as PLGA and ACA. One would have expected
ACC’s OPN expression to be higher due to its aggressive nature. As well, the
histological grading of MEC is determined by the proportion of mucous, intermediate and
squamous cells within the tumour. High grade tumours are predominately squamous
cells and low grade tumours are predominately mucous cells (1). Yet, a trend of
decreased OPN expression in squamous cells as compared to mucous cells was observed.
A possible explanation for this is that it is highly likely that there are other pathways
which are upregulated to facilitate metastasis and invasiveness other than OPN in SG
tumours. Also, as tumours become more anaplastic, they tend to lose epitopes which
help the tumours to evade the cellular immune response.
Our data suggested that OPN expression is not influenced by the gender of the patient in
either NSG or SG neoplasms. As OPN is a ubiquitous cytokine which acts on cellular
receptors via autocrine and paracrine mechanisms, one would not expect that gender
would play a role in its expression.
The age of the patient at the time of diagnosis demonstrated no specific trends with the
expression of OPN. One would expect decreased effectiveness and recruitment of innate
and acquired immunity with advanced age, but how this would affect cytokine expression
such as OPN levels and the recruitment of macrophages or t-lymphocytes could not be
elucidated with this study. The altered level of OPN expression may be a direct
reflection of the actual disease state, as increased expression of OPN may be related to
more clinically advanced disease.
The location of the disease, whether it is from minor or major SGs, had no effect on the
expression of OPN in this study.
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5.2 CD44
There were several studies that investigated the expression of CD44s and its variants in
various SG pathologies. Many of these studies demonstrated conflicting data regarding
whether CD44 is upregulated or downregulated in certain SG pathologies (41, 42, 92,
108, and 109). Yet, the general consensus regarding CD44v6 expression in non-SG
malignancies is that its upregulation yielded a poorer clinical outcome and prognosis
(92). The data from this study showed a uniform expression of CD44 pan-isoform in
ductal and non-ductal cells in all pathologies. CD44 in ductal cells was scantly or weakly
expressed, while CD44 was moderately expressed in non-ductal cells, such as acinar
cells. These findings were similar to those published in earlier studies (105, and 106). A
consistent observation throughout the study was the lack of IHC staining at the luminal
surface of ductal cells. As well, there seems to be a trend towards down-regulation of
CD44 in these benign and malignant SG tumours with the exception of ACA. One
explanation for this finding is the fact that PA, ACC and PLGA are tumours derived from
ductal components of SG, in which expression of CD44 is low as compared to non-ductal
components. MEC is a malignancy of the mucus cells of SGs with a malignant squamous
cells component. ACAs are tumours derived from serous acinar like cells, which are
upregulated in the non-ductal component of NSGs. It appears that tumours derived from
non-ductal components had increased overall CD44 expression compared to tumours
from ductal components. The significance of these findings cannot be determined by this
study. It is possible that CD44 may be used as an adjunctive marker to differentiate SG
tumour sub-type.

5.3 Integrin αvβ3
Numerous studies have looked at the expression of various integrin receptors in salivary
glands but, our study was the first to assess the expression pattern of integrin αvβ3 in
salivary glands and its pathologies (133, and 134). Integrin has been shown to be
important in the embryological development of salivary glands via its attachment to
fibronectin and collagen causing aggregation of integrin receptors such as α5β1, α2β1 and
α3β1 (133, and 134).
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Our study showed no detectable expression of integrin αvβ3 in either benign or normal SG
tissue, however, it is interesting to note that expression of integrin αvβ3 was demonstrated
in many endothelial cells, especially those undergoing inflammatory reactions. This is
likely related to neovascularization, as Dejana and Luscinskas have shown that blockage
of integrin αvβ3 affects β-FGF recruitment of endothelial cells for neovascularization
(135, 136). This is in contrast to 2 different studies which looked at individual monomer
expression of αv and β3 (107 and 134).
In our samples of malignant SG tumours, expression of integrin was not consistent
throughout, with the exception of ACA, where integrin was highly expressed (figure 412). Comparing all 4 selected groups of SG malignancies, the most indolent in this group
is low grade ACA with a high 5 years survival and cure rate (1). Yet, numerous studies
on integrin expression in other non-SG malignancies showed a correlation between
expression level and poorer clinical outcome and survival. One possible explanation for
our results is that integrin alone can be upregulated as a result of induction of
inflammatory cytokines as well as tumour derived cytokines; and other mechanisms or
ligands may be needed to induce tumour metastasis. Another interesting finding was that
in MEC the expression of integrin was occasionally found in mucus cells but not with
intermediate or squamous cells. ACC is considered to be the most aggressive and
relentless in this group of SG malignancies, due to its high propensity for perineural
invasion early in malignancy, yet it did not express αvβ3. This is likely because ACC
utilizes a different method of adhesion and migration other than integrin αvβ3.

5.4 Correlation study with OPN and its receptor CD44 and
integrin αvβ3
Interaction of OPN with its receptors such as CD44 or integrin is essential to exert its
physiological function such as activation and recruitment of lymphocytes. OPN has a
high affinity to hydroxyappetite (HA), and promotes cell attachment and migration via its
interaction with αv containing integrin, especially αvβ3 (137, 138, 139, and 140). As well,
OPN activation of integrin binding is further enhanced by the OPN-CD44 interaction,
especially with CD44v6 (141). With certain malignant tumours such as breast and
prostate, which have a high propensity to metastasize to bone, osteolytic activity is
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enhanced by OPN binding to osteoclast cell membranes via integrin receptors (130, and
131).
This is the first study which investigated the correlation between OPN and its receptors in
SG pathologies at the tissue level. At the present time, there have been several other
studies which examined only the expression of OPN, or CD44 in SG pathologies (30,
106, 107, 108, and 109). Our data showed that in general, there was a mildly positive
correlation between the expression of OPN and CD44 by NSG and MEC (Tables 4.7,
and 4.10), while there was a mildly negative correlation with PA and ACC (Tables 4.8,
and 4.9). Given that OPN expression is increased in malignant SG neoplasms and CD44
is decreased, it is likely that CD44 is not involved in malignant transformation of the SG
tumours studied. The only exception to this was with ACA, which showed a moderately
inversed relationship (Table 4.12). However, these trends were not statistically
significant. With PLGA, there was a significant moderate to strong correlation between
CD44 and OPN in both ductal and non-ductal cells (Table 4-11), as well a trend towards
moderate correlation between CD44 and integrin with non-ductal cells.
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Conclusions

In this study, our lab was able to characterize the expression of OPN in normal SG tissues
and in benign and malignant SG tumours. However there were differences in intensity of
expression. For example, OPN is highly expressed in the cytoplasm and nucleus of
ductal cells of normal salivary glands, but, OPN is sparsely expressed in mucous globules
of mucous acinar cells. And the amount of expression is generally increased in malignant
SG tumours as compared to that in the benign SG tumour and normal SG. However, we
did not demonstrate any significant differences in the amount of OPN expression between
various types of malignant SG tumours. In our sub-studies, OPN levels demonstrated a
moderate correlation with the histological grade in both PLGA and MEC. Thus, we
believe that OPN levels can potentially be useful in clinical diagnoses and would warrant
future prospective investigation. Recent studies have demonstrated detectible levels of
OPN in whole saliva (10 and 11), therefore, it may be useful to investigate and define a
normal reference level of OPN in the saliva of healthy individuals. This will assist in
determining whether there are differences between the OPN levels in the whole saliva of
healthy individual versus individuals with inflammatory or neoplastic conditions.
Our findings with CD44 (HCAM) were similar to previously published data by
Perschbacher et al. (106). However, this current study did not find a statistically
significant correlation between OPN and CD44 expression in any SG conditions.
Unfortunately, the available antibody used in this study was pan-isoform, and not a
specific antibody raised against a splice variant such as v6, which has been shown to be
up-regulated and able to interact with OPN in malignant tumours (41, and 128).
However, given there is a decreased expression of CD44 pan-isoform in SG neoplasms,
the likelihood of significant elevation of CD44v6 level is unlikely. Yet to be certain of
this claim, future investigations on the expression of CD44 with specific splice variants
(v6) and correlations with OPN in SG pathologies are warranted.
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The expression of integrin αvβ3 was only consistently found in acinic cell carcinoma
(ACA), but was inconsistently expressed in PLGA and MEC, and it was not detected in
ACC. Numerous studies have demonstrated an interaction between OPN and integrin
αvβ3 in various malignant tumours, and these markers have been correlated with a poor
clinical outcome (130, and 131). However, this current study found no such correlation
between OPN and integrin αvβ3, but, we cannot conclude that our findings are true
negative findings, or due to a lack of statistical power in our ACA group, which only had
a total of 11 samples. Thus, a larger sample size is indicated in the study of ACA.
Ultimately, it would be useful to assess the correlation of OPN and integrin αvβ3 with
other clinical data such as clinical stage, recurrence of disease, and mortality.
In summary this study was able to show:
1. A. OPN is upregulated in SG malignancy and may be useful as an aid to the
microscopic diagnosis of SG tumours; B. CD44 was not upregulated in SG
malignancy, and C. integrin αvβ3 was not upregulated in SG malignancy.
Therefore, these 2 markers are unlikely to be useful for microscopic diagnosis of
SG tumours.
2. We were not able to show any correlation between OPN expression and its
known receptors, CD44 and integrin αvβ3, in the SG neoplasms studied.
3. We were able to demonstrate a positive correlation between OPN but not CD44
nor integrin αvβ3 with pathological grade of specific SG malignancies (MEC and
ACC). Thus, OPN has the potential to be a useful prognostic marker for SG
malignancy.
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